BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ;  Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. [PMID: 15915461 DOI: 10.1002/hep.20701] [Cited by in Crossref: 5693] [Cited by in F6Publishing: 5491] [Article Influence: 334.9] [Reference Citation Analysis]
Number Citing Articles
1 Xu B, Jiang M, Chu Y, Wang W, Chen D, Li X, Zhang Z, Zhang D, Fan D, Nie Y, Shao F, Wu K, Liang J. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. Journal of Hepatology 2018;68:773-82. [DOI: 10.1016/j.jhep.2017.11.040] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 23.8] [Reference Citation Analysis]
2 Fernandes DM, Pantangi V, Azam M, Salomao M, Iuga AC, Lefkowitch JH, Gill J, Morotti R, Lavine JE, Mencin AA. Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study. The Journal of Pediatrics 2018;200:174-80. [DOI: 10.1016/j.jpeds.2018.04.047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
3 Yamanishi K, Maeda S, Kuwahara-Otani S, Watanabe Y, Yoshida M, Ikubo K, Okuzaki D, El-Darawish Y, Li W, Nakasho K, Nojima H, Yamanishi H, Hayakawa T, Okamura H, Matsunaga H. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl Res. 2016;173:101-114.e7. [PMID: 27063959 DOI: 10.1016/j.trsl.2016.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
4 Goldoni MB, Fontes PRO, GuimarÃes MM, Diedrich-Neto JA, Nogueira T, Teixeira UF, Giacomazzi CB, Kiss G, Pioner SR, Rodrigues PD. BYPASS VS. SLEEVE AND ITS EFFECTS IN NON-ALCOHOLIC FATTY LIVER DISEASE: WHAT IS THE BEST TECHNIQUE? Arq Bras Cir Dig 2021;33:e1549. [PMID: 33470379 DOI: 10.1590/0102-672020200003e1549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
6 Raszeja-Wyszomirska J, Safranow K, Milkiewicz M, Milkiewicz P, Szynkowska A, Stachowska E. Lipidic last breath of life in patients with alcoholic liver disease. Prostaglandins Other Lipid Mediat. 2012;99:51-56. [PMID: 22706383 DOI: 10.1016/j.prostaglandins.2012.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
7 Desjardin M, Desolneux G, Brouste V, Degrandi O, Bonhomme B, Fonck M, Becouarn Y, Béchade D, Evrard S. Parenchymal sparing surgery for colorectal liver metastases: The need for a common definition. Eur J Surg Oncol 2017;43:2285-91. [PMID: 29107396 DOI: 10.1016/j.ejso.2017.10.209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
8 Kinoshita M, Kubo S, Tanaka S, Takemura S, Nishioka T, Hamano G, Ito T, Tanaka S, Ohsawa M, Shibata T. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study: NASH and Intrahepatic Cholangiocarcinoma. J Surg Oncol 2016;113:779-83. [DOI: 10.1002/jso.24223] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
9 Lai CL, Wong D, Ip P, Kopaniszen M, Seto WK, Fung J, Huang FY, Lee B, Cullaro G, Chong CK, Wu R, Cheng C, Yuen J, Ngai V, Yuen MF. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281. [PMID: 27639844 DOI: 10.1016/j.jhep.2016.08.022] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 14.5] [Reference Citation Analysis]
10 Mózes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lupșor-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Yılmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2021:gutjnl-2021-324243. [PMID: 34001645 DOI: 10.1136/gutjnl-2021-324243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ke Z, Zhao Y, Tan S, Chen H, Li Y, Zhou Z, Huang C. Citrus reticulata Blanco peel extract ameliorates hepatic steatosis, oxidative stress and inflammation in HF and MCD diet-induced NASH C57BL/6 J mice. J Nutr Biochem 2020;83:108426. [PMID: 32559586 DOI: 10.1016/j.jnutbio.2020.108426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N. Hepatocellular ballooning in NASH. J Hepatol. 2010;53:719-723. [PMID: 20624660 DOI: 10.1016/j.jhep.2010.04.031] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
13 Massani M, Capovilla G, Ruffolo C, Bonariol R, Maccatrozzo P, Tuci F, Battistella G, Grazi GL, Bassi N. Blood transfusions and steatohepatitis are independent risk factors for complications following liver resection for colorectal cancer liver metastases. Mol Clin Oncol 2017;7:529-38. [PMID: 28855987 DOI: 10.3892/mco.2017.1358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T;  LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110. [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078] [Cited by in Crossref: 421] [Cited by in F6Publishing: 382] [Article Influence: 30.1] [Reference Citation Analysis]
15 Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 2008;48:1362-76. [PMID: 18972439 DOI: 10.1002/hep.22632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
16 Gill RM, Belt P, Wilson L, Bass NM, Ferrell LD. Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol. 2011;35:1400-1404. [PMID: 21836480 DOI: 10.1097/pas.0b013e3182254283] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
17 Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL, Yu ML. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712-718. [PMID: 19231011 DOI: 10.1016/j.jhep.2008.12.017] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 8.7] [Reference Citation Analysis]
18 Catrysse L, Farhang Ghahremani M, Vereecke L, Youssef SA, Mc Guire C, Sze M, Weber A, Heikenwalder M, de Bruin A, Beyaert R, van Loo G. A20 prevents chronic liver inflammation and cancer by protecting hepatocytes from death. Cell Death Dis 2016;7:e2250. [PMID: 27253414 DOI: 10.1038/cddis.2016.154] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
19 Santos-Baez LS, Ginsberg HN. Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol 2021;32:200-6. [PMID: 33883445 DOI: 10.1097/MOL.0000000000000756] [Reference Citation Analysis]
20 Sanyal AJ. NASH: A global health problem: NASH: A global health problem. Hepatology Research 2011;41:670-4. [DOI: 10.1111/j.1872-034x.2011.00824.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
21 Suga T, Yamaguchi H, Ogura J, Shoji S, Maekawa M, Mano N. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. Toxicol Appl Pharmacol 2019;379:114664. [PMID: 31306673 DOI: 10.1016/j.taap.2019.114664] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
22 Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, Paulweber B, Lackner C, Haufe H, Sotlar K, Datz C, Aigner E. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients. J Clin Med 2018;7:E562. [PMID: 30562976 DOI: 10.3390/jcm7120562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
23 Chatterjee A, Basu A, Das K, Chowdhury A, Basu P. Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. Gene 2021;775:145431. [PMID: 33444683 DOI: 10.1016/j.gene.2021.145431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Dal S, Van der Werf R, Walter C, Bietiger W, Seyfritz E, Mura C, Peronet C, Legrandois J, Werner D, Ennahar S, Digel F, Elisa MP, Pinget M, Jeandidier N, Marchioni E, Sigrist S. Treatment of NASH with Antioxidant Therapy: Beneficial Effect of Red Cabbage on Type 2 Diabetic Rats. Oxid Med Cell Longev 2018;2018:7019573. [PMID: 30363947 DOI: 10.1155/2018/7019573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yeh YT, Chiang AN, Hsieh SC. Chinese Olive (Canarium album L.) Fruit Extract Attenuates Metabolic Dysfunction in Diabetic Rats. Nutrients 2017;9:E1123. [PMID: 29036927 DOI: 10.3390/nu9101123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
26 Brea Á, Pintó X, Ascaso JF, Blasco M, Díaz Á, González-Santos P, Hernández Mijares A, Mantilla T, Millán J, Pedro-Botet J; Grupo de trabajo sobre Dislipemia Aterogénica. Sociedad Española de Arteriosclerosis. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease. Clin Investig Arterioscler 2017;29:141-8. [PMID: 27692633 DOI: 10.1016/j.arteri.2016.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, Olivero A, Marengo A, Rizzetto M, Bugianesi E, Smedile A. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis 2016;48:55-61. [PMID: 26514735 DOI: 10.1016/j.dld.2015.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
28 Levene AP, Kudo H, Armstrong MJ, Thursz MR, Gedroyc WM, Anstee QM, Goldin RD. Quantifying hepatic steatosis - more than meets the eye. Histopathology 2012;60:971-81. [PMID: 22372668 DOI: 10.1111/j.1365-2559.2012.04193.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
29 Choi N, Kim JW, Jeong H, Shin DG, Seo JH, Kim JH, Lim CW, Han KM, Kim B. Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model. J Ginseng Res 2019;43:196-208. [PMID: 30962734 DOI: 10.1016/j.jgr.2017.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
30 Borges VFDAE, Diniz ALD, Cotrim HP, Rocha HLOG, Salomão FC. Dopplerfluxometria da veia hepática em pacientes com esteatose não alcoólica. Radiol Bras 2011;44:1-6. [DOI: 10.1590/s0100-39842011000100005] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
31 Aparicio-Vergara M, Hommelberg PP, Schreurs M, Gruben N, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DP, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology. 2013;57:566-576. [PMID: 22941955 DOI: 10.1002/hep.26046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
32 Flister KFT, Pinto BAS, França LM, Coêlho CFF, Dos Santos PC, Vale CC, Kajihara D, Debbas V, Laurindo FRM, Paes AMA. Long-term exposure to high-sucrose diet down-regulates hepatic endoplasmic reticulum-stress adaptive pathways and potentiates de novo lipogenesis in weaned male mice. J Nutr Biochem 2018;62:155-66. [PMID: 30300835 DOI: 10.1016/j.jnutbio.2018.09.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
33 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PMID: 21248661 DOI: 10.1097/tp.0b013e31820b6b84] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
35 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16:124-132. [PMID: 20339187 DOI: 10.4103/1319-3767.61244] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
36 Jorge ASB, Andrade JMO, Paraíso AF, Jorge GCB, Silveira CM, de Souza LR, Santos EP, Guimaraes ALS, Santos SHS, De-paula AMB. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obesity Research & Clinical Practice 2018;12:1-8. [DOI: 10.1016/j.orcp.2016.03.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
37 Zhao X, Xue J, Wang X, Zhang Y, Deng M, Xie M. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats. International Immunopharmacology 2014;22:176-81. [DOI: 10.1016/j.intimp.2014.06.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
38 Liu Y, Chen H, Wang J, Zhou W, Sun R, Xia M. Association of serum retinoic acid with hepatic steatosis and liver injury in nonalcoholic fatty liver disease. Am J Clin Nutr. 2015;102:130-137. [PMID: 25948673 DOI: 10.3945/ajcn.114.105155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
39 Stanfliet JC, Locketz M, Berman P, Pillay TS. Evaluation of the utility of serum prolidase as a marker for liver fibrosis. J Clin Lab Anal 2015;29:208-13. [PMID: 24798655 DOI: 10.1002/jcla.21752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 Dzyubak B, Li J, Chen J, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, Allen AM, Yin M. Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021;54:122-31. [PMID: 33586159 DOI: 10.1002/jmri.27549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Askling J, Hultcrantz R, Kechagias S. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int 2019;39:197-204. [DOI: 10.1111/liv.13973] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
42 Ritze Y, Bárdos G, Hubert A, Böhle M, Bischoff SC. Effect of tryptophan supplementation on diet-induced non-alcoholic fatty liver disease in mice. Br J Nutr 2014;112:1-7. [PMID: 24708895 DOI: 10.1017/S0007114514000440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
43 Sun G, Jackson CV, Zimmerman K, Zhang LK, Finnearty CM, Sandusky GE, Zhang G, Peterson RG, Wang YJ. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose. BMC Gastroenterol 2019;19:41. [PMID: 30885145 DOI: 10.1186/s12876-019-0958-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
44 Cao H, Tuo L, Tuo Y, Xia Z, Fu R, Liu Y, Quan Y, Liu J, Yu Z, Xiang M. Immune and Metabolic Regulation Mechanism of Dangguiliuhuang Decoction against Insulin Resistance and Hepatic Steatosis. Front Pharmacol 2017;8:445. [PMID: 28736524 DOI: 10.3389/fphar.2017.00445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
45 Liu W, Zheng KI, Pan X, Ma H, Zhu P, Wu X, Rios RS, Targher G, Byrne CD, Wang X, Chen Y, Zheng M. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2020;35:1057-64. [DOI: 10.1111/jgh.14894] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
46 Jin R, Krasinskas A, Le N, Konomi JV, Holzberg J, Romero R, Vos MB. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease: PAI-1 and pediatric NAFLD. Pediatric Obesity 2018;13:23-9. [DOI: 10.1111/ijpo.12183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
47 Oral A, Sahin T, Turker F, Kocak E. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients. Medicina (Kaunas). 2019;55. [PMID: 31533345 DOI: 10.3390/medicina55090600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
48 Liu DP, Lu W, Zhang ZQ, Wang YB, Ding RR, Zhou XL, Huang D, Li XF. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. J Viral Hepat. 2018;25:581-589. [PMID: 29230907 DOI: 10.1111/jvh.12842] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
49 Naveau S, Lamouri K, Pourcher G, Njiké-Nakseu M, Ferretti S, Courie R, Tranchart H, Ghinoiu M, Balian A, Prévot S. The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD. Obes Surg. 2014;24:1693-1701. [PMID: 24841950 DOI: 10.1007/s11695-014-1235-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
50 Shen X, Chen Y, Zhang J, Yan X, Liu W, Guo Y, Shan Q, Liu S. Low-dose PCB126 compromises circadian rhythms associated with disordered glucose and lipid metabolism in mice. Environment International 2019;128:146-57. [DOI: 10.1016/j.envint.2019.04.058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
51 Nobel YR, Cox LM, Kirigin FF, Bokulich NA, Yamanishi S, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE, Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ. Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nat Commun 2015;6:7486. [PMID: 26123276 DOI: 10.1038/ncomms8486] [Cited by in Crossref: 213] [Cited by in F6Publishing: 194] [Article Influence: 30.4] [Reference Citation Analysis]
52 García-Martín R, Alexaki VI, Qin N, Rubín de Celis MF, Economopoulou M, Ziogas A, Gercken B, Kotlabova K, Phieler J, Ehrhart-Bornstein M, Bornstein SR, Eisenhofer G, Breier G, Blüher M, Hampe J, El-Armouche A, Chatzigeorgiou A, Chung KJ, Chavakis T. Adipocyte-Specific Hypoxia-Inducible Factor 2α Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. Mol Cell Biol 2016;36:376-93. [PMID: 26572826 DOI: 10.1128/MCB.00430-15] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
53 Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol. 2012;57:860-866. [PMID: 22668639 DOI: 10.1016/j.jhep.2012.05.019] [Cited by in Crossref: 149] [Cited by in F6Publishing: 156] [Article Influence: 14.9] [Reference Citation Analysis]
54 Germani G, Laryea M, Rubbia-Brandt L, Egawa H, Burra P, OʼGrady J, Watt KD. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation 2019;103:57-67. [PMID: 30335694 DOI: 10.1097/TP.0000000000002485] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 7.7] [Reference Citation Analysis]
55 El-Koofy N, El-Karaksy H, El-Akel W, Helmy H, Anwar G, El-Sayed R, El-Hennawy A. Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. Eur J Radiol 2012;81:3120-3. [PMID: 22817846 DOI: 10.1016/j.ejrad.2012.06.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
56 Zhong J, Gong W, Lu L, Chen J, Lu Z, Li H, Liu W, Liu Y, Wang M, Hu R, Long H, Wei L. Irbesartan ameliorates hyperlipidemia and liver steatosis in type 2 diabetic db/db mice via stimulating PPAR-γ, AMPK/Akt/mTOR signaling and autophagy. Int Immunopharmacol 2017;42:176-84. [PMID: 27919004 DOI: 10.1016/j.intimp.2016.11.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
57 Yao Q, Li S, Li X, Wang F, Tu C. Myricetin Modulates Macrophage Polarization and Mitigates Liver Inflammation and Fibrosis in a Murine Model of Nonalcoholic Steatohepatitis. Front Med 2020;7:71. [DOI: 10.3389/fmed.2020.00071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Osborne CS, Overstreet AN, Rockey DC, Schreiner AD. Drug-Induced Liver Injury Caused by Kratom Use as an Alternative Pain Treatment Amid an Ongoing Opioid Epidemic. J Investig Med High Impact Case Rep 2019;7:2324709619826167. [PMID: 30791718 DOI: 10.1177/2324709619826167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
59 Liou CJ, Wu SJ, Shen SC, Chen LC, Chen YL, Huang WC. Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice. Cell Biosci 2020;10:114. [PMID: 33014333 DOI: 10.1186/s13578-020-00477-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
60 Zarei A, Stasi C, Mahmoodi M, Masoumi SJ, Zare M, Jalali M. Effect of soy consumption on liver enzymes, lipid profile, anthropometry indices, and oxidative stress in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Iran J Basic Med Sci 2020;23:1245-50. [PMID: 33149855 DOI: 10.22038/ijbms.2020.46854.10797] [Reference Citation Analysis]
61 Zhu X, Yan H, Chang X, Xia M, Zhang L, Wang L, Sun X, Yang X, Gao X, Bian H. Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation. BMJ Open Diabetes Res Care 2020;8:e000999. [PMID: 32759166 DOI: 10.1136/bmjdrc-2019-000999] [Reference Citation Analysis]
62 Dey P, Kim JB, Chitchumroonchokchai C, Li J, Sasaki GY, Olmstead BD, Stock KL, Thomas-Ahner JM, Clinton SK, Bruno RS. Green tea extract inhibits early oncogenic responses in mice with nonalcoholic steatohepatitis. Food Funct 2019;10:6351-61. [PMID: 31503268 DOI: 10.1039/c9fo01199d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
63 Al-sharhan F, Dohan A, Barat M, Feddal A, Terris B, Pol S, Mallet V, Soyer P. MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH). European Journal of Radiology 2019;119:108648. [DOI: 10.1016/j.ejrad.2019.108648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
64 Levin PD, Weissman C. Obesity, metabolic syndrome, and the surgical patient. Anesthesiol Clin 2009;27:705-19. [PMID: 19942175 DOI: 10.1016/j.anclin.2009.09.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Wu C, Zhou Y, Wang M, Dai G, Liu X, Lai L, Tang S. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. Front Genet 2021;12:772487. [PMID: 34777484 DOI: 10.3389/fgene.2021.772487] [Reference Citation Analysis]
66 Sagnelli C, Merli M, Uberti-Foppa C, Hasson H, Grandone A, Cirillo G, Salpietro S, Minichini C, Starace M, Messina E, Morelli P, Miraglia Del Giudice E, Lazzarin A, Coppola N, Sagnelli E. TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. World J Gastroenterol 2016; 22(38): 8509-8518 [PMID: 27784963 DOI: 10.3748/wjg.v22.i38.8509] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
67 Wang X, Ren Q, Wu T, Guo Y, Liang Y, Liu S. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice. Mol Med Rep 2014;10:2917-23. [PMID: 25310357 DOI: 10.3892/mmr.2014.2623] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
68 Micioni Di Bonaventura MV, Coman MM, Tomassoni D, Micioni Di Bonaventura E, Botticelli L, Gabrielli MG, Rossolini GM, Di Pilato V, Cecchini C, Amedei A, Silvi S, Verdenelli MC, Cifani C. Supplementation with Lactiplantibacillus plantarum IMC 510 Modifies Microbiota Composition and Prevents Body Weight Gain Induced by Cafeteria Diet in Rats. Int J Mol Sci 2021;22:11171. [PMID: 34681831 DOI: 10.3390/ijms222011171] [Reference Citation Analysis]
69 Horvath S, Erhart W, Brosch M, Ammerpohl O, von Schönfels W, Ahrens M, Heits N, Bell JT, Tsai PC, Spector TD. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci USA. 2014;111:15538-15543. [PMID: 25313081 DOI: 10.1073/pnas.1412759111] [Cited by in Crossref: 407] [Cited by in F6Publishing: 355] [Article Influence: 50.9] [Reference Citation Analysis]
70 Navarro CDC, Francisco A, Figueira TR, Ronchi JA, Oliveira HCF, Vercesi AE, Castilho RF. Dichloroacetate reactivates pyruvate-supported peroxide removal by liver mitochondria and prevents NAFLD aggravation in NAD(P)+ transhydrogenase-null mice consuming a high-fat diet. Eur J Pharmacol 2022;:174750. [PMID: 35032488 DOI: 10.1016/j.ejphar.2022.174750] [Reference Citation Analysis]
71 Mizuno N, Seko Y, Kataoka S, Okuda K, Furuta M, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Itoh Y. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. J Gastroenterol 2019;54:160-70. [PMID: 29948305 DOI: 10.1007/s00535-018-1485-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
72 Gharib AM, Han MAT, Meissner EG, Kleiner DE, Zhao X, McLaughlin M, Matthews L, Rizvi B, Abd-Elmoniem KZ, Sinkus R, Levy E, Koh C, Myers RP, Subramanian GM, Kottilil S, Heller T, Kovacs JA, Morse CG. Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. Biomed Res Int 2017;2017:2067479. [PMID: 28480218 DOI: 10.1155/2017/2067479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
73 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
74 Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, Hartmann A, Bosserhoff AK, Hellerbrand C. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut 2015;64:973-81. [PMID: 25011936 DOI: 10.1136/gutjnl-2014-306968] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
75 Shin SS, Yoon M. The herbal composition GGEx18 from Laminaria japonica, Rheum palmatum , and Ephedra sinica inhibits high-fat diet-induced hepatic steatosis via hepatic PPARα activation. Pharmaceutical Biology 2012;50:1261-8. [DOI: 10.3109/13880209.2012.666982] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
76 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
77 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
78 Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, Brosnan MJ, Böcskei Z, Anstee QM, Bossuyt PM, Zafarmand MH, Pavlides M, Levick C, Duffin K, Hyde C, Bauer T, Bedossa P, Leeming D, Daly A, Hanf R, Ortiz P, Oresic M, Schuppan D, Hanauer G, Chen Y, Shumbayawonda E, Bjerring PN, Zwinderman K. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology 2020;73:252-62. [DOI: 10.1016/j.jhep.2020.03.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 16.0] [Reference Citation Analysis]
79 Yamada K, Mizukoshi E, Sunagozaka H, Arai K, Yamashita T, Takeshita Y, Misu H, Takamura T, Kitamura S, Zen Y, Nakanuma Y, Honda M, Kaneko S. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 2015;35:582-590. [PMID: 25219574 DOI: 10.1111/liv.12685] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
80 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
81 Zhou X, Fouda S, Zeng XY, Li D, Zhang K, Xu J, Ye JM. Characterization of the Therapeutic Profile of Albiflorin for the Metabolic Syndrome. Front Pharmacol 2019;10:1151. [PMID: 31680948 DOI: 10.3389/fphar.2019.01151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Srivastava J, Robertson CL, Ebeid K, Dozmorov M, Rajasekaran D, Mendoza R, Siddiq A, Akiel MA, Jariwala N, Shen XN, Windle JJ, Subler MA, Mukhopadhyay ND, Giashuddin S, Ghosh S, Lai Z, Chen Y, Fisher PB, Salem AK, Sanyal AJ, Sarkar D. A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH). Hepatology 2017;66:466-80. [PMID: 28437865 DOI: 10.1002/hep.29230] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
83 Zarrouki B, Boucher J. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis. Methods Mol Biol 2020;2164:121-7. [PMID: 32607889 DOI: 10.1007/978-1-0716-0704-6_13] [Reference Citation Analysis]
84 Hamaguchi M, Okamura T, Fukuda T, Nishida K, Yoshimura Y, Hashimoto Y, Ushigome E, Nakanishi N, Majima S, Asano M, Yamazaki M, Takakuwa H, Kita M, Fukui M. Group 3 Innate Lymphoid Cells Protect Steatohepatitis From High-Fat Diet Induced Toxicity. Front Immunol 2021;12:648754. [PMID: 33790913 DOI: 10.3389/fimmu.2021.648754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
85 Li J, Liu H, Mauer AS, Lucien F, Raiter A, Bandla H, Mounajjed T, Yin Z, Glaser KJ, Yin M, Malhi H. Characterization of Cellular Sources and Circulating Levels of Extracellular Vesicles in a Dietary Murine Model of Nonalcoholic Steatohepatitis. Hepatol Commun 2019;3:1235-49. [PMID: 31497744 DOI: 10.1002/hep4.1404] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
86 Okada LSDRR, Oliveira CP, Stefano JT, Nogueira MA, Silva IDCGD, Cordeiro FB, Alves VAF, Torrinhas RS, Carrilho FJ, Puri P, Waitzberg DL. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH – Proteomic and lipidomic insight. Clinical Nutrition 2018;37:1474-84. [DOI: 10.1016/j.clnu.2017.08.031] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
87 Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med. 2012;7 Suppl 3:S291-S296. [PMID: 23073870 DOI: 10.1007/s11739-012-0819-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
88 Castera L. Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab. 2008;34:674-679. [PMID: 19195629 DOI: 10.1016/s1262-3636(08)74603-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
89 Leivas G, Maraschin CK, Blume CA, Telo GH, Trindade MRM, Trindade EN, Diemen VV, Cerski CTS, Schaan BD. Accuracy of ultrasound diagnosis of nonalcoholic fatty liver disease in patients with classes II and III obesity: A pathological image study. Obes Res Clin Pract 2021;15:461-5. [PMID: 34511367 DOI: 10.1016/j.orcp.2021.09.002] [Reference Citation Analysis]
90 Soon RK, Yan JS, Grenert JP, Maher JJ. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. Gastroenterology. 2010;139:1730-1739, 1739.e1. [PMID: 20682321 DOI: 10.1053/j.gastro.2010.07.046] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
91 Klair JS, Yang JD, Abdelmalek MF, Guy CD, Gill RM, Yates K, Unalp-Arida A, Lavine JE, Clark JM, Diehl AM, Suzuki A;  Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology. 2016;64:85-91. [PMID: 26919573 DOI: 10.1002/hep.28514] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
92 Kim H, Park M, Shin JH, Kwon O. Ethanolic Extract of Acanthopanax koreanum Nakai Alleviates Alcoholic Liver Damage Combined with a High-Fat Diet in C57BL/6J Mice. Molecules 2016;21:E681. [PMID: 27231887 DOI: 10.3390/molecules21060681] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
93 Himoto T, Yoneyama H, Kurokohchi K, Mori H, Inukai M, Masugata H, Goda F, Haba R, Watanabe S, Senda S, Masaki T. Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C. J Clin Lab Anal 2012;26:342-8. [PMID: 23001979 DOI: 10.1002/jcla.21529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
94 Soto-Luna IC, García-López PM, Vargas-Guerrero B, Guzmán TJ, Domínguez-Rosales JA, Gurrola-Díaz CM. Lupin protein isolate improves insulin sensitivity and steatohepatitis in vivo and modulates the expression of the Fasn, Gys2, and Gsk3b genes. Food Sci Nutr 2021;9:2549-60. [PMID: 34026071 DOI: 10.1002/fsn3.2206] [Reference Citation Analysis]
95 Fang JZ, Li C, Liu XY, Hu TT, Fan ZS, Han ZG. Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma. PLoS One 2015;10:e0143042. [PMID: 26569409 DOI: 10.1371/journal.pone.0143042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
96 Elzinga SE, Savelieff MG, O'Brien PD, Mendelson FE, Hayes JM, Feldman EL. Sex differences in insulin resistance, but not peripheral neuropathy, in a diet-induced prediabetes mouse model. Dis Model Mech 2021;14:dmm048909. [PMID: 33692086 DOI: 10.1242/dmm.048909] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
97 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
98 Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, Galle PR, Wörns MA, Anstee QM, Schuppan D, Schattenberg JM. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 2018;48:1109-16. [PMID: 30288767 DOI: 10.1111/apt.14976] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
99 Vonghia L, Magrone T, Verrijken A, Michielsen P, Van Gaal L, Jirillo E, Francque S. Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. PLoS One 2015;10:e0143380. [PMID: 26599575 DOI: 10.1371/journal.pone.0143380] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
100 Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Medicine (Baltimore). 2015;94:e2159. [PMID: 26632897 DOI: 10.1097/md.0000000000002159] [Cited by in Crossref: 46] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
101 Soroida Y, Nakatsuka T, Sato M, Nakagawa H, Tanaka M, Yamauchi N, Wake T, Nakagomi R, Kinoshita MN, Minami T, Uchino K, Enooku K, Asaoka Y, Tanaka Y, Endo M, Nakamura A, Kobayashi T, Kurihara M, Hikita H, Sato M, Gotoh H, Iwai T, Fukayama M, Ikeda H, Tateishi R, Yatomi Y, Koike K. A Novel Non-invasive Method for Predicting Liver Fibrosis by Quantifying the Hepatic Vein Waveform. Ultrasound in Medicine & Biology 2019;45:2363-71. [DOI: 10.1016/j.ultrasmedbio.2019.05.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Osna NA, Feng D, Ganesan M, Maillacheruvu PF, Orlicky DJ, French SW, Tuma DJ, Kharbanda KK. Prolonged feeding with guanidinoacetate, a methyl group consumer, exacerbates ethanol-induced liver injury. World J Gastroenterol 2016; 22(38): 8497-8508 [PMID: 27784962 DOI: 10.3748/wjg.v22.i38.8497] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
103 Cheong H, Lee SS, Lee JS, Kim J, Kim SW, Lee WJ. Phagocytic function of Kupffer cells in mouse nonalcoholic fatty liver disease models: Evaluation with superparamagnetic iron oxide. J Magn Reson Imaging. 2015;41:1218-1227. [PMID: 24916329 DOI: 10.1002/jmri.24674] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
104 Shetty A, Giron F, Divatia MK, Ahmad MI, Kodali S, Victor D. Nonalcoholic Fatty Liver Disease after Liver Transplant. J Clin Transl Hepatol 2021;9:428-35. [PMID: 34221929 DOI: 10.14218/JCTH.2020.00072] [Reference Citation Analysis]
105 Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2012;27:341-350. [PMID: 21929649 DOI: 10.1111/j.1440-1746.2011.06939.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
106 Bacle A, Kadri L, Khoury S, Ferru-Clément R, Faivre JF, Cognard C, Bescond J, Krzesiak A, Contzler H, Delpech N, Colas J, Vandebrouck C, Sébille S, Ferreira T. A comprehensive study of phospholipid fatty acid rearrangements in metabolic syndrome: correlations with organ dysfunction. Dis Model Mech 2020;13:dmm043927. [PMID: 32303571 DOI: 10.1242/dmm.043927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
107 Chenxu G, Minxuan X, Yuting Q, Tingting G, Jing F, Jinxiao L, Sujun W, Yongjie M, Deshuai L, Qiang L, Linfeng H, Xuyuan N, Mingxing W, Ping H, Jun T. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress. Free Radical Biology and Medicine 2019;134:23-41. [DOI: 10.1016/j.freeradbiomed.2018.12.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
108 Liu Q, Nie H, Xu H, Wang P, Lei P. Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum. Korean J Radiol 2021;22:155-8. [PMID: 32767866 DOI: 10.3348/kjr.2020.0492] [Reference Citation Analysis]
109 Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010;51:3046-3054. [PMID: 20631297 DOI: 10.1194/jlr.m007096] [Cited by in Crossref: 170] [Cited by in F6Publishing: 86] [Article Influence: 14.2] [Reference Citation Analysis]
110 Sun D, Zhang L, Chen H, Feng R, Cao P, Liu Y. Effects of Antarctic krill oil on lipid and glucose metabolism in C57BL/6J mice fed with high fat diet. Lipids Health Dis 2017;16:218. [PMID: 29157255 DOI: 10.1186/s12944-017-0601-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
111 Belza C, Thompson R, Somers GR, de Silva N, Fitzgerald K, Steinberg K, Courtney-martin G, Wales PW, Avitzur Y. Persistence of hepatic fibrosis in pediatric intestinal failure patients treated with intravenous fish oil lipid emulsion. Journal of Pediatric Surgery 2017;52:795-801. [DOI: 10.1016/j.jpedsurg.2017.01.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
112 Jian C, Fu J, Cheng X, Shen L, Ji Y, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang H, Zhang X, Wang Y, Huang Z, She Z, Zhang X, Zhu L, Li H. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metabolism 2020;31:892-908.e11. [DOI: 10.1016/j.cmet.2020.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
113 Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. Ann Diagn Pathol 2018;37:83-90. [PMID: 30312882 DOI: 10.1016/j.anndiagpath.2018.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
114 Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol. 2014;24:959-966. [PMID: 24463697 DOI: 10.1007/s00330-014-3096-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
115 Skoien R, Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-tetri BA, Bhathal PS, Dixon JB, O'brien PE, Tilg H, Moschen AR, Baumann U, Brown RM, Couper RT, Manton ND, Ee LC, Weltman M, Clouston AD. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013;33:624-32. [DOI: 10.1111/liv.12100] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
116 Georgoulis M, Kontogianni MD, Tileli N, Margariti A, Fragopoulou E, Tiniakos D, Zafiropoulou R, Papatheodoridis G. The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr 2014;53:1727-35. [DOI: 10.1007/s00394-014-0679-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
117 Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, Versiani CA, Vidigal PVT, Ferrari TCA, Couto CA. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020; 12(10): 792-806 [PMID: 33200017 DOI: 10.4254/wjh.v12.i10.792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34:e302-e307. [PMID: 24313922 DOI: 10.1111/liv.12429] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 10.5] [Reference Citation Analysis]
119 Amini R, Nosrati N, Yazdanparast R, Molaei M. Teucrium polium in prevention of steatohepatitis in rats. Liver International 2009;29:1216-21. [DOI: 10.1111/j.1478-3231.2009.02033.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
120 Reeves JG, Suriawinata AA, Ng DP, Holubar SD, Mills JB, Barth RJ. Short-term preoperative diet modification reduces steatosis and blood loss in patients undergoing liver resection. Surgery 2013;154:1031-7. [DOI: 10.1016/j.surg.2013.04.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
121 Ohashi T, Kato M, Yamasaki A, Kuwano A, Suzuki H, Kohjima M, Ogawa Y. Effects of high fructose intake on liver injury progression in high fat diet induced fatty liver disease in ovariectomized female mice. Food Chem Toxicol 2018;118:190-7. [PMID: 29751074 DOI: 10.1016/j.fct.2018.05.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
122 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
123 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Kanno R, Koshizuka T, Miyazaki N, Kobayashi T, Ishioka K, Ozaki C, Chiba H, Suzutani T. Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. Foods 2021;10:291. [PMID: 33535476 DOI: 10.3390/foods10020291] [Reference Citation Analysis]
125 Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015;60:1440-7. [PMID: 25540086 DOI: 10.1007/s10620-014-3494-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
126 Yu S, Wen Y, Li J, Zhang H, Liu Y. Prenatal Lipopolysaccharide Exposure Promotes Dyslipidemia in the Male Offspring Rats. Front Physiol 2018;9:542. [PMID: 29867579 DOI: 10.3389/fphys.2018.00542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
127 Lukowicz C, Ellero-Simatos S, Régnier M, Oliviero F, Lasserre F, Polizzi A, Montagner A, Smati S, Boudou F, Lenfant F, Guzylack-Pirou L, Menard S, Barretto S, Fougerat A, Lippi Y, Naylies C, Bertrand-Michel J, Belgnaoui AA, Theodorou V, Marchi N, Gourdy P, Gamet-Payrastre L, Loiseau N, Guillou H, Mselli-Lakhal L. Dimorphic metabolic and endocrine disorders in mice lacking the constitutive androstane receptor. Sci Rep 2019;9:20169. [PMID: 31882815 DOI: 10.1038/s41598-019-56570-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
128 Brunt EM, Kleiner DE. Challenges in the hepatic histopathology in non-alcoholic fatty liver disease. Gut 2017;66:1539-40. [PMID: 28159834 DOI: 10.1136/gutjnl-2016-313379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
129 Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Duarte-Rojo A, Elkashab M, Myers RP. The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatol Int 2013;7:592-9. [PMID: 26201792 DOI: 10.1007/s12072-012-9401-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
130 Gwag T, Reddy Mooli RG, Li D, Lee S, Lee EY, Wang S. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease. JHEP Rep 2021;3:100193. [PMID: 33294831 DOI: 10.1016/j.jhepr.2020.100193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
131 Fishman P, Cohen S, Itzhak I, Amer J, Salhab A, Barer F, Safadi R. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice. Int J Mol Med 2019;44:2256-64. [PMID: 31638172 DOI: 10.3892/ijmm.2019.4364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
132 Emma MR, Giannitrapani L, Cabibi D, Porcasi R, Pantuso G, Augello G, Giglio RV, Re NL, Capitano AR, Montalto G, Soresi M, Cervello M. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158792. [PMID: 32777481 DOI: 10.1016/j.bbalip.2020.158792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13(47): 6419-6424 [PMID: 18081233 DOI: 10.3748/wjg.v13.i47.6419] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 125] [Article Influence: 7.4] [Reference Citation Analysis]
134 Degrassi I, Deheragoda M, Creegen D, Mundy H, Mustafa A, Vara R, Hadzic N. Liver histology in children with glycogen storage disorders type VI and IX. Dig Liver Dis 2021;53:86-93. [PMID: 32505569 DOI: 10.1016/j.dld.2020.04.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
135 Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A; NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008;48:829-34. [PMID: 18321606 DOI: 10.1016/j.jhep.2008.01.016] [Cited by in Crossref: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
136 Gim JA, Bang SM, Lee YS, Lee Y, Yim SY, Jung YK, Kim H, Kim BH, Kim JH, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. PLoS One 2021;16:e0255822. [PMID: 34358264 DOI: 10.1371/journal.pone.0255822] [Reference Citation Analysis]
137 Senates E, Yilmaz Y, Colak Y, Ozturk O, Altunoz ME, Kurt R, Ozkara S, Aksaray S, Tuncer I, Ovunc AOK. Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 2011;9:287-90. [DOI: 10.1089/met.2010.0121] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
138 Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120-127. [PMID: 29409822 DOI: 10.1016/j.metabol.2018.01.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
139 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A. The UCP2 -866 G& gt; A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574-1580. [PMID: 25351290 DOI: 10.1111/liv.12707] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
140 Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-822. [PMID: 19012034 DOI: 10.1007/s00535-008-2213-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 7.4] [Reference Citation Analysis]
141 Yilmaz Y, Eren F, Colak Y, Senates E, Celikel CA, Imeryuz N. Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2012;47:1488-93. [PMID: 23137022 DOI: 10.3109/00365521.2012.725093] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
142 Honma M, Sawada S, Ueno Y, Murakami K, Yamada T, Gao J, Kodama S, Izumi T, Takahashi K, Tsukita S, Uno K, Imai J, Kakazu E, Kondo Y, Mizuno K, Kawagishi N, Shimosegawa T, Katagiri H. Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. Int J Obes (Lond) 2018;42:1544-55. [PMID: 29717275 DOI: 10.1038/s41366-018-0062-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
143 Wang MH, Palmeri ML, Guy CD, Yang L, Hedlund LW, Diehl AM, Nightingale KR. In vivo quantification of liver stiffness in a rat model of hepatic fibrosis with acoustic radiation force. Ultrasound Med Biol 2009;35:1709-21. [PMID: 19683381 DOI: 10.1016/j.ultrasmedbio.2009.04.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
144 Brunner SF, Roberts ND, Wylie LA, Moore L, Aitken SJ, Davies SE, Sanders MA, Ellis P, Alder C, Hooks Y, Abascal F, Stratton MR, Martincorena I, Hoare M, Campbell PJ. Somatic mutations and clonal dynamics in healthy and cirrhotic human liver. Nature 2019;574:538-42. [PMID: 31645727 DOI: 10.1038/s41586-019-1670-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 30.0] [Reference Citation Analysis]
145 Wang X, Liu R, Zhang W, Zhang X, Liao N, Wang Z, Li W, Qin X, Hai C. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Mol Cell Endocrinol 2013;376:70-80. [PMID: 23791844 DOI: 10.1016/j.mce.2013.06.014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 9.3] [Reference Citation Analysis]
146 Pirola CJ, Flichman D, Dopazo H, Fernández Gianotti T, San Martino J, Rohr C, Garaycoechea M, Gazzi C, Castaño GO, Sookoian S. A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis. Hepatol Commun 2018;2:1030-6. [PMID: 30202818 DOI: 10.1002/hep4.1235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
147 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
148 Tian Y, Arai E, Makiuchi S, Tsuda N, Kuramoto J, Ohara K, Takahashi Y, Ito N, Ojima H, Hiraoka N, Gotoh M, Yoshida T, Kanai Y. Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas. J Cancer Res Clin Oncol 2020;146:2461-77. [PMID: 32685988 DOI: 10.1007/s00432-020-03298-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
149 Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009;19:291-302. [PMID: 19359149 DOI: 10.1016/j.numecd.2008.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 189] [Article Influence: 15.2] [Reference Citation Analysis]
150 Kim JK, Lee KS, Lee DK, Lee SY, Chang HY, Choi J, Lee JI. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. Exp Mol Med 2014;46:e127. [PMID: 25523099 DOI: 10.1038/emm.2014.90] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
151 Duseja A, Chahal GS, Jain A, Mehta M, Ranjan A, Grover V. Association between nonalcoholic fatty liver disease and inflammatory periodontal disease: A case‑control study. J Indian Soc Periodontol 2021;25:47-54. [PMID: 33642741 DOI: 10.4103/jisp.jisp_45_20] [Reference Citation Analysis]
152 Zakaria Z, Othman ZA, Suleiman JB, Che Jalil NA, Ghazali WSW, Nna VU, Mohamed M. Hepatoprotective Effect of Bee Bread in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Rats: Impact on Oxidative Stress and Inflammation. Antioxidants (Basel) 2021;10:2031. [PMID: 34943134 DOI: 10.3390/antiox10122031] [Reference Citation Analysis]
153 Robinson EJ, Taddeo MC, Chu X, Shi W, Wood C, Still C, Rovnyak VG, Rovnyak D. Aqueous Metabolite Trends for the Progression of Nonalcoholic Fatty Liver Disease in Female Bariatric Surgery Patients by Targeted 1H-NMR Metabolomics. Metabolites 2021;11:737. [PMID: 34822395 DOI: 10.3390/metabo11110737] [Reference Citation Analysis]
154 Zeng X, Yang J, Hu O, Huang J, Ran L, Chen M, Zhang Y, Zhou X, Zhu J, Zhang Q, Yi L, Mi M. Dihydromyricetin Ameliorates Nonalcoholic Fatty Liver Disease by Improving Mitochondrial Respiratory Capacity and Redox Homeostasis Through Modulation of SIRT3 Signaling. Antioxid Redox Signal. 2019;30:163-183. [PMID: 29310441 DOI: 10.1089/ars.2017.7172] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 13.3] [Reference Citation Analysis]
155 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
156 Janczyk W, Socha P. Non-alcoholic fatty liver disease in children. Clin Res Hepatol Gastroenterol. 2012;36:297-300. [PMID: 22521558 DOI: 10.1016/j.clinre.2012.03.026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
157 Ægidius HM, Veidal SS, Feigh M, Hallenborg P, Puglia M, Pers TH, Vrang N, Jelsing J, Kornum BR, Blagoev B, Rigbolt KTG. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Sci Rep 2020;10:1148. [PMID: 31980690 DOI: 10.1038/s41598-020-58059-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
158 Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, Chen W. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. Journal of Functional Foods 2021;82:104496. [DOI: 10.1016/j.jff.2021.104496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
159 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 22] [Article Influence: 16.7] [Reference Citation Analysis]
160 Rogers AM. Comment on: histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis 2018;14:1616-7. [PMID: 30228081 DOI: 10.1016/j.soard.2018.08.010] [Reference Citation Analysis]
161 Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int 2021;41:1853-66. [PMID: 33788377 DOI: 10.1111/liv.14888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
162 Kim RG, Nguyen P, Bettencourt R, Dulai PS, Haufe W, Hooker J, Minocha J, Valasek MA, Aryafar H, Brenner DA, Sirlin CB, Loomba R. Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study. Aliment Pharmacol Ther 2016;44:287-99. [PMID: 27279429 DOI: 10.1111/apt.13691] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
163 Korkmaz H, Unler GK, Gokturk HS, Schmidt WE, Kebapcilar L. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test: . European Journal of Gastroenterology & Hepatology 2015;27:1137-43. [DOI: 10.1097/meg.0000000000000407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
164 Viganò M, Valenti L, Lampertico P, Facchetti F, Motta BM, D'ambrosio R, Romagnoli S, Dongiovanni P, Donati B, Fargion S, Colombo M. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B: Hepatology, Vol. 58, No. X, 2013. Hepatology 2013;58:1245-52. [DOI: 10.1002/hep.26445] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
165 Yuan G, Tan M, Chen X. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice. Food Funct 2021;12:7897-908. [PMID: 34241611 DOI: 10.1039/d1fo01152a] [Reference Citation Analysis]
166 Kukuk GM, Hittatiya K, Sprinkart AM, Eggers H, Gieseke J, Block W, Moeller P, Willinek WA, Spengler U, Trebicka J, Fischer HP, Schild HH, Träber F. Comparison between modified Dixon MRI techniques, MR spectroscopic relaxometry, and different histologic quantification methods in the assessment of hepatic steatosis. Eur Radiol 2015;25:2869-79. [PMID: 25903702 DOI: 10.1007/s00330-015-3703-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
167 Ma Y, Zhang M, Yu H, Lu J, Cheng KKY, Zhou J, Chen H, Jia W. Activation of G0/G1 switch gene 2 by endoplasmic reticulum stress enhances hepatic steatosis. Metabolism 2019;99:32-44. [PMID: 31271806 DOI: 10.1016/j.metabol.2019.06.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Yang Y, Jiang Y, Wang Y, An W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie 2010;92:958-63. [PMID: 20385201 DOI: 10.1016/j.biochi.2010.04.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
169 Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, Wang LJ, Zheng RD, Zhang HW, Ling WH, Zhu HL. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076. [PMID: 26743949 DOI: 10.1038/srep19076] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 20.3] [Reference Citation Analysis]
170 Zhou Y, Ding Y, Zhang J, Zhang P, Wang J, Li Z. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomedicine & Pharmacotherapy 2018;97:1397-408. [DOI: 10.1016/j.biopha.2017.10.035] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
171 Kim SW, Hur W, Li TZ, Lee YK, Choi JE, Hong SW, Lyoo KS, You CR, Jung ES, Jung CK, Park T, Um SJ, Yoon SK. Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice. Exp Mol Med 2014;46:e92. [PMID: 24763197 DOI: 10.1038/emm.2014.10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
172 Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, Farrell GC. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419-1425. [PMID: 18853998 DOI: 10.1111/j.1440-1746.2008.05531.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
173 Schuster S, Johnson CD, Hennebelle M, Holtmann T, Taha AY, Kirpich IA, Eguchi A, Ramsden CE, Papouchado BG, McClain CJ, Feldstein AE. Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice. J Lipid Res 2018;59:1597-609. [PMID: 30084831 DOI: 10.1194/jlr.M083741] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
174 Weiss J, Rau M, Meertens J, Hering I, Reichert L, Kudlich T, Koschker A, Jurowich C, Geier A. Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. Scandinavian Journal of Gastroenterology 2016;51:1263-8. [DOI: 10.1080/00365521.2016.1191084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
175 Li C, Ye J, Prince M, Peng Y, Dou W, Shang S, Wu J, Luo X. Comparing mono-exponential, bi-exponential, and stretched-exponential diffusion-weighted MR imaging for stratifying non-alcoholic fatty liver disease in a rabbit model. Eur Radiol 2020;30:6022-32. [PMID: 32591883 DOI: 10.1007/s00330-020-07005-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem. 2009;42:802-807. [PMID: 19217891 DOI: 10.1016/j.clinbiochem.2009.02.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
177 Ozturk A, Grajo JR, Gee MS, Benjamin A, Zubajlo RE, Thomenius KE, Anthony BW, Samir AE, Dhyani M. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. Ultrasound Med Biol 2018;44:2461-75. [PMID: 30232020 DOI: 10.1016/j.ultrasmedbio.2018.07.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
178 Bantel H, John K, Schulze-osthoff K. Robust Detection of Liver Steatosis and Staging of NAFLD by an Improved ELISA for Serum Cytokeratin-18 Fragments. American Journal of Gastroenterology 2014;109:140-1. [DOI: 10.1038/ajg.2013.350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
179 Capitan V, Petit J, Aho S, Lefevre P, Favelier S, Loffroy R, Hillon P, Krausé D, Cercueil J, Guiu B. Macroscopic heterogeneity of liver fat: an MR-based study in type-2 diabetic patients. Eur Radiol 2012;22:2161-8. [DOI: 10.1007/s00330-012-2468-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
180 Colak Y, Senates E, Ozturk O, Doganay HL, Coskunpinar E, Oltulu YM, Eren A, Sahin O, Ozkanli S, Enc FY. Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2012;10:103-109. [PMID: 22112193 DOI: 10.1089/met.2011.0111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
181 Bastati N, Feier D, Wibmer A, Traussnigg S, Balassy C, Tamandl D, Einspieler H, Wrba F, Trauner M, Herold C, Ba-Ssalamah A. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology. 2014;271:739-747. [PMID: 24576046 DOI: 10.1148/radiol.14131890] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
182 Hupfeld S, Pischel D, Jechorek D, Janicová A, Pech M, Fischbach F. MRI-based fat quantification of the liver: Is it time for commercially available products? Eur J Radiol 2021;144:109993. [PMID: 34656047 DOI: 10.1016/j.ejrad.2021.109993] [Reference Citation Analysis]
183 Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009;18:144-51. [PMID: 19573756 DOI: 10.1053/j.sempedsurg.2009.04.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
184 Wernberg CW, Ravnskjaer K, Lauridsen MM, Thiele M. The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. J Clin Med 2021;10:930. [PMID: 33804302 DOI: 10.3390/jcm10050930] [Reference Citation Analysis]
185 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
186 Edens MA, van Ooijen PM, Post WJ, Haagmans MJ, Kristanto W, Sijens PE, van der Jagt EJ, Stolk RP. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity (Silver Spring). 2009;17:2239-2244. [PMID: 19461588 DOI: 10.1038/oby.2009.154] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
187 Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007;133:80-90. [PMID: 17631134 DOI: 10.1053/j.gastro.2007.05.012] [Cited by in Crossref: 317] [Cited by in F6Publishing: 295] [Article Influence: 21.1] [Reference Citation Analysis]
188 Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E5237. [PMID: 31652578 DOI: 10.3390/ijms20205237] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
189 Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, Minamiguchi S, Maekawa T, Uemoto S, Haga H. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl. 2012;18:1333-1342. [PMID: 22888064 DOI: 10.1002/lt.23534] [Cited by in Crossref: 132] [Cited by in F6Publishing: 105] [Article Influence: 14.7] [Reference Citation Analysis]
190 Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation. J Nutr 2017;147:1938-46. [PMID: 28814531 DOI: 10.3945/jn.117.254292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
191 Xie L, Wang PX, Zhang P, Zhang XJ, Zhao GN, Wang A, Guo J, Zhu X, Zhang Q, Li H. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. J Hepatol. 2016;65:113-124. [PMID: 27016281 DOI: 10.1016/j.jhep.2016.03.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
192 Aron-Wisnewsky J, Clement K, Pépin JL. Nonalcoholic fatty liver disease and obstructive sleep apnea. Metabolism 2016;65:1124-35. [PMID: 27324067 DOI: 10.1016/j.metabol.2016.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
193 Calès P, Boursier J, Chaigneau J, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Cavaro-Ménard C, Gallois Y, Deugnier Y, Rousselet MC. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 2010;30:1346-54. [PMID: 20666992 DOI: 10.1111/j.1478-3231.2010.02314.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
194 Bateman AC. Patterns of histological change in liver disease: my approach to ‘medical’ liver biopsy reporting. Histopathology 2007;51:585-96. [DOI: 10.1111/j.1365-2559.2007.02765.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
195 Ma SY, Sun KS, Zhang M, Zhou X, Zheng XH, Tian SY, Liu YS, Chen L, Gao X, Ye J, Zhou XM, Wang JB, Han Y. Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD. Liver Int 2020;40:2427-38. [PMID: 32339374 DOI: 10.1111/liv.14492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
196 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015;47:603-15. [PMID: 25534430 DOI: 10.1007/s00726-014-1894-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 11.1] [Reference Citation Analysis]
197 Li N, Xie G, Zhou B, Qu A, Meng H, Liu J, Wang G. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease. Front Physiol 2021;12:696163. [PMID: 34366886 DOI: 10.3389/fphys.2021.696163] [Reference Citation Analysis]
198 Colombo S, Belloli L, Zaccanelli M, Badia E, Jamoletti C, Buonocore M, Del Poggio P. Normal liver stiffness and its determinants in healthy blood donors. Dig Liver Dis. 2011;43:231-236. [PMID: 20817625 DOI: 10.1016/j.dld.2010.07.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
199 Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, Silva GF, Geyvandova N, Stanciu C, Rabbia M, McKenna M, Thommes JA, Harrison SA; PROGRESS Study Investigators. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology 2010;139:1972-83. [PMID: 20816836 DOI: 10.1053/j.gastro.2010.08.051] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
200 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID: 32553765 DOI: 10.1053/j.gastro.2020.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 25.0] [Reference Citation Analysis]
201 Pellanda H, Forges T, Bressenot A, Chango A, Bronowicki J, Guéant J, Namour F. Fumonisin FB1 treatment acts synergistically with methyl donor deficiency during rat pregnancy to produce alterations of H3- and H4-histone methylation patterns in fetuses. Mol Nutr Food Res 2012;56:976-85. [DOI: 10.1002/mnfr.201100640] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
202 Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. J Clin Transl Hepatol 2021;9:40-50. [PMID: 33604254 DOI: 10.14218/JCTH.2020.00055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Takamoto T, Hashimoto T, Sano K, Maruyama Y, Inoue K, Ogata S, Takemura T, Kokudo N, Makuuchi M. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol 2010;17:2747-55. [PMID: 20425145 DOI: 10.1245/s10434-010-1074-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
204 van Rijn RR, Nievelstein RA. Paediatric ultrasonography of the liver, hepatobiliary tract and pancreas. Eur J Radiol 2014;83:1570-81. [PMID: 24780818 DOI: 10.1016/j.ejrad.2014.03.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
205 Yu W, Hu S, Qi Y, Li B. The correlation between sonographic diagnosis and laparoscopic observations on fatty liver. J Laparoendosc Adv Surg Tech A 2009;19:163-9. [PMID: 19216696 DOI: 10.1089/lap.2008.0311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
206 Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int. 2014;34:129-135. [PMID: 23809459 DOI: 10.1111/liv.12230] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
207 Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H. (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus 2013;2:690. [PMID: 25674420 DOI: 10.1186/2193-1801-2-690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
208 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894-903. [PMID: 20684021 DOI: 10.1002/hep.23759.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
209 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP, Subramanian GM, McHutchison JG, Goodman ZD, Afdhal NH, Charlton MR; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67:549-559. [PMID: 28892558 DOI: 10.1002/hep.29514] [Cited by in Crossref: 249] [Cited by in F6Publishing: 254] [Article Influence: 49.8] [Reference Citation Analysis]
210 Hsieh J, Koseki M, Molusky MM, Yakushiji E, Ichi I, Westerterp M, Iqbal J, Chan RB, Abramowicz S, Tascau L, Takiguchi S, Yamashita S, Welch CL, Di Paolo G, Hussain MM, Lefkowitch JH, Rader DJ, Tall AR. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature 2016;535:303-7. [PMID: 27383786 DOI: 10.1038/nature18628] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
211 Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, Mccolgan BJ, Mchutchison JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afdhal NH, Goodman Z, Bosch J, Sanyal AJ. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology 2018;155:1140-53. [DOI: 10.1053/j.gastro.2018.07.006] [Cited by in Crossref: 114] [Cited by in F6Publishing: 113] [Article Influence: 28.5] [Reference Citation Analysis]
212 Corey KE, Misdraji J, Zheng H, Malecki KM, Kneeman J, Gelrud L, Chung RT. The absence of obstructive sleep apnea may protect against non-alcoholic fatty liver in patients undergoing bariatric surgery. PLoS One. 2013;8:e62504. [PMID: 23658732 DOI: 10.1371/journal.pone.0062504] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
213 Ali AH, Panchal S, Rao DS, Gan Y, Al-Juboori A, Samiullah S, Ibdah JA, Hammoud GM. The efficacy and safety of endoscopic ultrasound-guided liver biopsy versus percutaneous liver biopsy in patients with chronic liver disease: a retrospective single-center study. J Ultrasound 2020;23:157-67. [PMID: 32141043 DOI: 10.1007/s40477-020-00436-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
214 Moore A, Wu L, Chuang JC, Sun X, Luo X, Gopal P, Li L, Celen C, Zimmer M, Zhu H. Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation. Hepatology 2019;69:1931-45. [PMID: 30584660 DOI: 10.1002/hep.30487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
215 Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism. 2016;65:1297-1306. [PMID: 27506737 DOI: 10.1016/j.metabol.2016.05.013] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 9.5] [Reference Citation Analysis]
216 Espino A, Villagrán A, Vollrath V, Hanckes P, Salas R, Farah A, Solís N, Pizarro M, Escalona A, Boza C, Pérez G, Carrasco G, Padilla O, Francisco Miquel J, Nervi F, C. Chavez-tapia N, Pablo Arab J, Álvarez-lobos M, Arrese M, Riquelme A. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. Annals of Hepatology 2011;10:493-501. [DOI: 10.1016/s1665-2681(19)31518-2] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
217 Eguchi A, Mizukami S, Nakamura M, Masuda S, Murayama H, Kawashima M, Inohana M, Nagahara R, Kobayashi M, Yamashita R, Uomoto S, Makino E, Ohtsuka R, Takahashi N, Hayashi SM, Maronpot RR, Shibutani M, Yoshida T. Metronidazole enhances steatosis-related early-stage hepatocarcinogenesis in high fat diet-fed rats through DNA double-strand breaks and modulation of autophagy. Environ Sci Pollut Res Int 2021. [PMID: 34341928 DOI: 10.1007/s11356-021-15689-2] [Reference Citation Analysis]
218 Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. [PMID: 24637477 DOI: 10.1371/journal.pone.0091987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
219 Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, Chim AM, Chu S, Chan FK, Sung JJ, Chan HL. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009;29:387-96. [PMID: 19035982 DOI: 10.1111/j.1365-2036.2008.03896.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
220 Wang XM, Wang XY, Huang YM, Chen X, Lü MH, Shi L, Li CP. Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease. Int J Mol Med 2019;44:2201-12. [PMID: 31638173 DOI: 10.3892/ijmm.2019.4375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
221 Pitisuttithum P, Chan WK, Goh GBB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Dan YY, Imajo K, Nakajima A, Ho KY, Goh KL, Wong VWS, Treeprasertsuk S. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative. World J Gastroenterol 2020; 26(19): 2416-2426 [PMID: 32476802 DOI: 10.3748/wjg.v26.i19.2416] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
222 Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-91. [PMID: 19896127 DOI: 10.1016/j.atherosclerosis.2009.10.011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
223 Li Q, Li M, Li F, Zhou W, Dang Y, Zhang L, Ji G. Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice. J Ethnopharmacol 2020;258:112896. [PMID: 32325178 DOI: 10.1016/j.jep.2020.112896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
224 Du Y, Paglicawan L, Soomro S, Abunofal O, Baig S, Vanarsa K, Hicks J, Mohan C. Epigallocatechin-3-Gallate Dampens Non-Alcoholic Fatty Liver by Modulating Liver Function, Lipid Profile and Macrophage Polarization. Nutrients 2021;13:599. [PMID: 33670347 DOI: 10.3390/nu13020599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, Oflaz H, Ozdogan O, Imeryuz N, Kalayci C. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver fibrosis. Atherosclerosis. 2010;211:182-186. [PMID: 20181335 DOI: 10.1016/j.atherosclerosis.2010.01.049] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
226 Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012;29:1098-1107. [PMID: 22672330 DOI: 10.1111/j.1464-5491.2012.03732.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
227 Mikuriya Y, Tashiro H, Kobayashi T, Kuroda S, Abe T, Hashimoto M, Ohdan H. Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Langenbecks Arch Surg 2015;400:471-6. [PMID: 25744657 DOI: 10.1007/s00423-015-1295-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
228 Villalpando-Arteaga EV, Mendieta-Condado E, Esquivel-Solís H, Canales-Aguirre AA, Gálvez-Gastélum FJ, Mateos-Díaz JC, Rodríguez-González JA, Márquez-Aguirre AL. Hibiscus sabdariffa L. aqueous extract attenuates hepatic steatosis through down-regulation of PPAR-γ and SREBP-1c in diet-induced obese mice. Food Funct 2013;4:618-26. [PMID: 23389749 DOI: 10.1039/c3fo30270a] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
229 Rangwala F, Guy CD, Lu J, Suzuki A, Burchette JL, Abdelmalek MF, Chen W, Diehl AM. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol. 2011;224:401-410. [PMID: 21547909 DOI: 10.1002/path.2888] [Cited by in Crossref: 105] [Cited by in F6Publishing: 93] [Article Influence: 9.5] [Reference Citation Analysis]
230 Kuraji R, Ito H, Fujita M, Ishiguro H, Hashimoto S, Numabe Y. Porphyromonas gingivalis induced periodontitis exacerbates progression of non-alcoholic steatohepatitis in rats. Clin Exp Dent Res 2016;2:216-25. [PMID: 29744170 DOI: 10.1002/cre2.41] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
231 Nishikawa T, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Mizuno Y, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Ichino N, Osakabe K, Yoshioka K. Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. World J Gastroenterol 2014; 20(5): 1289-1297 [PMID: 24574802 DOI: 10.3748/wjg.v20.i5.1289] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
232 Shinkawa H, Tanaka S, Takemura S, Ito T, Aota T, Koda M, Miyazaki T, Yamamoto T, Kubo S. Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Ann Gastroenterol Surg 2018;2:319-26. [PMID: 30003195 DOI: 10.1002/ags3.12183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
233 Choi JH, Necsoiu C, Wendorff D, Jordan B, Dixon A, Roberts TR, Beely BM, Cancio LC, Batchinsky AI. Effects of adjunct treatments on end-organ damage and histological injury severity in acute respiratory distress syndrome and multiorgan failure caused by smoke inhalation injury and burns. Burns 2019;45:1765-74. [PMID: 31378621 DOI: 10.1016/j.burns.2019.07.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
234 Sookoian S, Castaño GO, Scian R, San Martino J, Pirola CJ. Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). Sci Rep 2016;6:22528. [PMID: 26935030 DOI: 10.1038/srep22528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
235 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 25.5] [Reference Citation Analysis]
236 Hsu TH, Tsui PH, Yu WT, Huang SF, Tai J, Wan YL, Tai DI. Cutoff Values of Acoustic Radiation Force Impulse Two-Location Measurements in Different Etiologies of Liver Fibrosis. J Med Ultrasound 2019;27:130-4. [PMID: 31867175 DOI: 10.4103/JMU.JMU_7_19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
237 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Collins AR, Gupte AA, Ji R, Ramirez MR, Minze LJ, Liu JZ, Arredondo M, Ren Y, Deng T, Wang J. Myeloid deletion of nuclear factor erythroid 2-related factor 2 increases atherosclerosis and liver injury. Arterioscler Thromb Vasc Biol. 2012;32:2839-2846. [PMID: 23023374 DOI: 10.1161/atvbaha.112.300345] [Cited by in Crossref: 56] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
239 Zen Y, Kondou H, Nakazawa A, Tanikawa K, Hasegawa Y, Bessho K, Imagawa K, Ishige T, Inui A, Suzuki M, Kasahara M, Yamamoto K, Yoshioka T, Kage M, Hayashi H. Proposal of a liver histology-based scoring system for bile salt export pump deficiency. Hepatol Res 2020;50:754-62. [PMID: 32073700 DOI: 10.1111/hepr.13494] [Reference Citation Analysis]
240 Arai T, Atsukawa M, Tsubota A, Koeda M, Yoshida Y, Okubo T, Nakagawa A, Itokawa N, Kondo C, Nakatsuka K, Masu T, Kato K, Shimada N, Hatori T, Emoto N, Kage M, Iwakiri K. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dig Liver Dis. 2019;51:1036-1042. [PMID: 30683615 DOI: 10.1016/j.dld.2018.12.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
241 Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2021;126:154911. [PMID: 34648769 DOI: 10.1016/j.metabol.2021.154911] [Reference Citation Analysis]
242 Zhang L, Shen L, Xu D, Wang L, Guo Y, Liu Z, Liu Y, Liu L, Magdalou J, Chen L, Wang H. Increased susceptibility of prenatal food restricted offspring to high-fat diet-induced nonalcoholic fatty liver disease is intrauterine programmed. Reproductive Toxicology 2016;65:236-47. [DOI: 10.1016/j.reprotox.2016.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
243 Costa G, Cavinato L, Masci C, Fiz F, Sollini M, Politi LS, Chiti A, Balzarini L, Aghemo A, di Tommaso L, Ieva F, Torzilli G, Viganò L. Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases. Cancers (Basel) 2021;13:3077. [PMID: 34203103 DOI: 10.3390/cancers13123077] [Reference Citation Analysis]
244 Kumar S, Srivastava A, Palaia T, Hall C, Lee J, Stevenson M, Zhao CL, Ragolia L. Lipocalin-type prostaglandin D2 synthase deletion induces dyslipidemia and non-alcoholic fatty liver disease. Prostaglandins & Other Lipid Mediators 2020;149:106429. [DOI: 10.1016/j.prostaglandins.2020.106429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Dai Y, Zhu J, Meng D, Yu C, Li Y. Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis. J Clin Biochem Nutr 2016;58:76-83. [PMID: 26798201 DOI: 10.3164/jcbn.15-54] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
246 Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87. [DOI: 10.1002/hep.22848] [Cited by in Crossref: 785] [Cited by in F6Publishing: 768] [Article Influence: 60.4] [Reference Citation Analysis]
247 Su YM, Lv GR, Xie JX, Wang ZH, Lin HT. Maternal hypoxia increases the susceptibility of adult rat male offspring to high-fat diet-induced nonalcoholic fatty liver disease. Endocrinology 2013;154:4377-87. [PMID: 24002036 DOI: 10.1210/en.2012-1683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
248 Claude JA, Grimm A, Savage HP, Pinkerton KE. Perinatal exposure to environmental tobacco smoke (ETS) enhances susceptibility to viral and secondary bacterial infections. Int J Environ Res Public Health 2012;9:3954-64. [PMID: 23202826 DOI: 10.3390/ijerph9113954] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
249 Choi Y, Abdelmegeed MA, Song BJ. Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL/6J female mice: Role of disturbed lipid homeostasis and increased oxidative stress. Food Chem Toxicol 2017;103:111-21. [PMID: 28257781 DOI: 10.1016/j.fct.2017.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
250 Alsaqal S, Hockings P, Ahlström H, Gummesson A, Hedström A, Hulthe J, Johansson L, Niessen HG, Schoelch C, Schultheis C, Vessby J, Wanders A, Rorsman F, Ebeling Barbier C. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis. J Magn Reson Imaging 2021. [PMID: 34953171 DOI: 10.1002/jmri.28040] [Reference Citation Analysis]
251 Sun W, Cui H, Li N, Wei Y, Lai S, Yang Y, Yin X, Chen DF. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016;46:862-870. [PMID: 26763834 DOI: 10.1111/hepr.12647] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 11.3] [Reference Citation Analysis]
252 Andrade GCD, Fujise LH, Santana Filho JED, Oliveira F, Silva RDCMAD. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras 2016;62:218-26. [DOI: 10.1590/1806-9282.62.03.218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
253 Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. [PMID: 17096854 DOI: 10.1186/1471-230x-6-34] [Cited by in Crossref: 186] [Cited by in F6Publishing: 72] [Article Influence: 11.6] [Reference Citation Analysis]
254 Traussnigg S, Kienbacher C, Gajdošík M, Valkovič L, Halilbasic E, Stift J, Rechling C, Hofer H, Steindl-Munda P, Ferenci P, Wrba F, Trattnig S, Krššák M, Trauner M. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. Liver Int 2017;37:1544-53. [PMID: 28544208 DOI: 10.1111/liv.13451] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
255 Harrison SA, Dennis A, Fiore MM, Kelly MD, Kelly CJ, Paredes AH, Whitehead JM, Neubauer S, Traber PG, Banerjee R. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One 2018;13:e0203054. [PMID: 30192782 DOI: 10.1371/journal.pone.0203054] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
256 El-Derany MO. Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis. Biology (Basel) 2020;9:E75. [PMID: 32283835 DOI: 10.3390/biology9040075] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
257 Chen YC, Jeng WJ, Hsu CW, Lin CY. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol 2020;20:146. [PMID: 32397963 DOI: 10.1186/s12876-020-01289-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
258 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2020;115:1289-92. [PMID: 32453041 DOI: 10.14309/ajg.0000000000000676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
259 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
260 Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv 2017;24:932-41. [PMID: 28617150 DOI: 10.1080/10717544.2017.1337823] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
261 Giraudi PJ, Becerra VJ, Marin V, Chavez-Tapia NC, Tiribelli C, Rosso N. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp Mol Pathol. 2015;98:85-92. [PMID: 25533546 DOI: 10.1016/j.yexmp.2014.12.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
262 Seidman JS, Troutman TD, Sakai M, Gola A, Spann NJ, Bennett H, Bruni CM, Ouyang Z, Li RZ, Sun X, Vu BT, Pasillas MP, Ego KM, Gosselin D, Link VM, Chong LW, Evans RM, Thompson BM, McDonald JG, Hosseini M, Witztum JL, Germain RN, Glass CK. Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. Immunity 2020;52:1057-1074.e7. [PMID: 32362324 DOI: 10.1016/j.immuni.2020.04.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 29.5] [Reference Citation Analysis]
263 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 115] [Article Influence: 12.1] [Reference Citation Analysis]
264 Reisman SA, Ferguson DA, Lee CI, Proksch JW. Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis. J Biochem Mol Toxicol 2020;:e22526. [PMID: 32410268 DOI: 10.1002/jbt.22526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
265 Steensels S, Qiao J, Zhang Y, Maner-Smith KM, Kika N, Holman CD, Corey KE, Bracken WC, Ortlund EA, Ersoy BA. Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver. Hepatology 2020;72:857-72. [PMID: 32498134 DOI: 10.1002/hep.31409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
266 Pose E, Pera G, Torán P, Gratacós-Ginès J, Avitabile E, Expósito C, Díaz A, Graupera I, Rubio AB, Ginès P, Fabrellas N, Caballeria L. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. Liver Int 2021;41:1556-64. [PMID: 33595176 DOI: 10.1111/liv.14830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Shiffman ML, Sterling RK, Contos M, Hubbard S, Long A, Luketic VA, Stravitz RT, Fuchs M, Sanyal AJ. Long term changes in liver histology following treatment of chronic hepatitis C virus. Annals of Hepatology 2014;13:340-9. [DOI: 10.1016/s1665-2681(19)30840-3] [Cited by in Crossref: 29] [Article Influence: 3.6] [Reference Citation Analysis]
268 Willebrords J, Maes M, Pereira IVA, da Silva TC, Govoni VM, Lopes VV, Crespo Yanguas S, Shestopalov VI, Nogueira MS, de Castro IA, Farhood A, Mannaerts I, van Grunsven L, Akakpo J, Lebofsky M, Jaeschke H, Cogliati B, Vinken M. Protective effect of genetic deletion of pannexin1 in experimental mouse models of acute and chronic liver disease. Biochim Biophys Acta Mol Basis Dis 2018;1864:819-30. [PMID: 29246445 DOI: 10.1016/j.bbadis.2017.12.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
269 Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. [PMID: 21678341 DOI: 10.1002/14651858.cd003619.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
270 Galimberti S, Trombini P, Bernasconi DP, Redaelli I, Pelucchi S, Bovo G, Di Gennaro F, Zucchini N, Paruccini N, Piperno A. Simultaneous liver iron and fat measures by magnetic resonance imaging in patients with hyperferritinemia. Scandinavian Journal of Gastroenterology 2015;50:429-38. [DOI: 10.3109/00365521.2014.940380] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
271 Thomsen KL, Grønbæk H, Glavind E, Hebbard L, Jessen N, Clouston A, George J, Vilstrup H. Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. Am J Physiol Gastrointest Liver Physiol 2014;307:G295-301. [PMID: 24924745 DOI: 10.1152/ajpgi.00036.2014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
272 Milei J, Losada MO, Llambí HG, Grana DR, Suárez D, Azzato F, Ambrosio G. Chronic cola drinking induces metabolic and cardiac alterations in rats. World J Cardiol 2011; 3(4): 111-116 [PMID: 21526048 DOI: 10.4330/wjc.v3.i4.111] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
273 Belemets N, Kobyliak N, Virchenko O, Falalyeyeva T, Olena T, Bodnar P, Savchuk O, Galenova T, Caprnda M, Rodrigo L, Skladany L, Delev D, Opatrilova R, Kruzliak P, Beregova T, Ostapchenko L. Effects of polyphenol compounds melanin on NAFLD/NASH prevention. Biomedicine & Pharmacotherapy 2017;88:267-76. [DOI: 10.1016/j.biopha.2017.01.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
274 Elshazly SM. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. European Journal of Pharmacology 2015;748:123-32. [DOI: 10.1016/j.ejphar.2014.12.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
275 Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, Lavín Trueba JL, Mayo R, Ilisso CP, de Juan VG, Iruarrizaga-Lejarreta M, delaCruz-Villar L, Mincholé I, Robinson A, Crespo J, Martín-Duce A, Romero-Gómez M, Sann H, Platon J, Van Eyk J, Aspichueta P, Noureddin M, Falcón-Pérez JM, Anguita J, Aransay AM, Martínez-Chantar ML, Lu SC, Mato JM. Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis. Gastroenterology 2017;152:1449-1461.e7. [PMID: 28132890 DOI: 10.1053/j.gastro.2017.01.015] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 24.0] [Reference Citation Analysis]
276 Strey CBM, de Carli LA, Fantinelli M, Gobbato SS, Bassols GF, Losekann A, Coral GP. Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese. Ann Hepatol 2018;17:585-91. [PMID: 29893699 DOI: 10.5604/01.3001.0012.0922] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
277 Zhang N, Wang Y, Zhang J, Liu B, Deng X, Xin S, Xu K. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARα and SCD-1. FASEB J 2020;34:15338-63. [PMID: 32996649 DOI: 10.1096/fj.202000836RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Al-Fayoumi S, Hashiguchi T, Shirakata Y, Mascarenhas J, Singer JW. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis. J Exp Pharmacol 2018;10:9-17. [PMID: 29785143 DOI: 10.2147/JEP.S150729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
279 Lønsmann I, Gudmann NS, Manon-jensen T, Thiele M, Moreno YM, Langholm LL, Nielsen MJ, Detlefsen S, Karsdal MA, Krag AA, Leeming DJ. Serologically assessed heat shock protein 47 is related to fibrosis stage in early compensated alcohol-related liver disease. Clinical Biochemistry 2021. [DOI: 10.1016/j.clinbiochem.2021.12.008] [Reference Citation Analysis]
280 Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y, Sonoda K, Tsuchikura S, Yasui N, Ikeda K. Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med. 2012;17:173-182. [PMID: 21853259 DOI: 10.1007/s12199-011-0235-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
281 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
282 Bartuzi P, Wijshake T, Dekker DC, Fedoseienko A, Kloosterhuis NJ, Youssef SA, Li H, Shiri-Sverdlov R, Kuivenhoven JA, de Bruin A, Burstein E, Hofker MH, van de Sluis B. A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta 2014;1842:2257-65. [PMID: 25072958 DOI: 10.1016/j.bbadis.2014.06.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
283 Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J;  International Liver Disease Genetics Consortium. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64:34-46. [PMID: 26822232 DOI: 10.1002/hep.28475] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
284 Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. [PMID: 18537181 DOI: 10.1002/hep.22336] [Cited by in Crossref: 272] [Cited by in F6Publishing: 243] [Article Influence: 19.4] [Reference Citation Analysis]
285 Tzeng TF, Liou SS, Chang CJ, Liu IM. 6-gingerol protects against nutritional steatohepatitis by regulating key genes related to inflammation and lipid metabolism. Nutrients 2015;7:999-1020. [PMID: 25658238 DOI: 10.3390/nu7020999] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
286 Cotrim HP, Freitas LA, Alves E, Almeida A, May DS, Caldwell S. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol. 2009;21:969-972. [PMID: 19194305 DOI: 10.1097/meg.0b013e328328f3ec] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
287 Xiang M, Wang PX, Wang AB, Zhang XJ, Zhang Y, Zhang P, Mei FH, Chen MH, Li H. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol. 2016;64:1365-1377. [PMID: 26860405 DOI: 10.1016/j.jhep.2016.02.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 13.3] [Reference Citation Analysis]
288 Nadanaka S, Hashiguchi T, Kitagawa H. Aberrant glycosaminoglycan biosynthesis by tumor suppressor EXTL2 deficiency promotes liver inflammation and tumorigenesis through Toll-like 4 receptor signaling. FASEB J 2020;34:8385-401. [PMID: 32347583 DOI: 10.1096/fj.201902076R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
289 Angelini G, Castagneto Gissey L, Del Corpo G, Giordano C, Cerbelli B, Severino A, Manco M, Basso N, Birkenfeld AL, Bornstein SR, Genco A, Mingrone G, Casella G. New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery. Sci Rep 2019;9:17315. [PMID: 31754142 DOI: 10.1038/s41598-019-53702-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
290 Hubert C, Lucidi V, Weerts J, Dili A, Demetter P, Massart B, Komuta M, Navez J, Reding R, Gigot J, Sempoux C. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases. European Journal of Surgical Oncology 2018;44:1532-8. [DOI: 10.1016/j.ejso.2018.07.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
291 Nam HH, Jun DW, Jang K, Saeed WK, Lee JS, Kang HT, Chae YJ. Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization. Oncotarget. 2017;8:97965-97976. [PMID: 29228666 DOI: 10.18632/oncotarget.18967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
292 Miele L, Forgione A, La Torre G, Vero V, Cefalo C, Racco S, Vellone VG, Vecchio FM, Gasbarrini G, Rapaccini GL, Neuman MG, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease. Transl Res. 2009;154:194-201. [PMID: 19766963 DOI: 10.1016/j.trsl.2009.06.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
293 Rausch V, Peccerella T, Lackner C, Yagmur E, Seitz HK, Longerich T, Mueller S. Primary liver injury and delayed resolution of liver stiffness after alcohol detoxification in heavy drinkers with the PNPLA3 variant I148M. World J Hepatol 2016; 8(35): 1547-1556 [PMID: 28050235 DOI: 10.4254/wjh.v8.i35.1547] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
294 Ling J, Chaba T, Zhu LF, Jacobs RL, Vance DE. Hepatic ratio of phosphatidylcholine to phosphatidylethanolamine predicts survival after partial hepatectomy in mice. Hepatology 2012;55:1094-102. [PMID: 22095799 DOI: 10.1002/hep.24782] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
295 Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van Houten EL, Visser JA, Morgan SA, Lavery GG. Loss of 5α-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology. 2013;154:4536-4547. [PMID: 24080367 DOI: 10.1210/en.2013-1592] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
296 Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931-1938. [PMID: 17511754 DOI: 10.1111/j.1572-0241.2007.01322.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 6.9] [Reference Citation Analysis]
297 Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep 2021;11:5845. [PMID: 33712681 DOI: 10.1038/s41598-021-85186-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
298 Charchanti A, Kanavaros P, Koniaris E, Kataki A, Glantzounis G, Agnantis NJ, Goussia AC. Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis. In Vivo 2021;35:333-9. [PMID: 33402482 DOI: 10.21873/invivo.12264] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Jiang M, Wu N, Chen X, Wang W, Chu Y, Liu H, Li W, Chen D, Li X, Xu B. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. J Int Med Res 2019;47:1453-66. [PMID: 30871397 DOI: 10.1177/0300060519833527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
300 Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132:783-792. [PMID: 23535911 DOI: 10.1007/s00439-013-1294-3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 12.6] [Reference Citation Analysis]
301 Takeshita Y, Kanamori T, Tanaka T, Kaikoi Y, Kita Y, Takata N, Iida N, Arai K, Yamashita T, Harada K, Gabata T, Nakamura H, Kaneko S, Takamura T. Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Diabetes Ther 2020;11:549-60. [PMID: 31956961 DOI: 10.1007/s13300-020-00762-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
302 Mowry CJ, Alonso C, Iruarrizaga-Lejarreta M, Ortiz P, Levitsky J, Rinella M. Utility of Metabolomic Biomarkers to Identify Nonalcoholic Fatty Liver Disease in Liver Transplant Recipients. Transplant Direct 2021;7:e784. [PMID: 34778544 DOI: 10.1097/TXD.0000000000001227] [Reference Citation Analysis]
303 Boeykens N, Ponsaerts P, Van der Linden A, Berneman Z, Ysebaert D, De Greef K. Injury-dependent retention of intraportally administered mesenchymal stromal cells following partial hepatectomy of steatotic liver does not lead to improved liver recovery. PLoS One. 2013;8:e69092. [PMID: 23874878 DOI: 10.1371/journal.pone.0069092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
304 Chun YS, Laurent A, Maru D, Vauthey J. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. The Lancet Oncology 2009;10:278-86. [DOI: 10.1016/s1470-2045(09)70064-6] [Cited by in Crossref: 107] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
305 Sanai FM, Babatin MA, Bzeizi KI, Alsohaibani F, Al-Hamoudi W, Alsaad KO, Al Mana H, Handoo FA, Al-Ashgar H, Alghamdi H. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol. 2013;11:1493-1499.e2. [PMID: 23811251 DOI: 10.1016/j.cgh.2013.05.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
306 Seo HI, Cho YK, Lee WY, Rhee EJ, Sung KC, Kim BS, Son BH, Shin JH, Joo KJ, Hong HP, Chae SW, Jin W. Which metabolic syndrome criteria best predict the presence of non-alcoholic fatty liver disease? Diabetes Research and Clinical Practice 2012;95:19-24. [DOI: 10.1016/j.diabres.2011.08.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
307 Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT, Wang D, Wei Y, Jiang H, Orlicky DJ, Petersen DR, Pagliassotti MJ, Maclean KN. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease. Am J Physiol Regul Integr Comp Physiol 2011;301:R1710-22. [PMID: 21957160 DOI: 10.1152/ajpregu.00677.2010] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
308 Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
309 Kara M, Dogru T, Genc H, Sertoglu E, Celebi G, Gurel H, Kayadibi H, Cicek AF, Ercin CN, Sonmez A. Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1144-1148. [PMID: 26062078 DOI: 10.1097/meg.0000000000000405] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
310 Sang T, Guo C, Guo D, Wu J, Wang Y, Wang Y, Chen J, Chen C, Wu K, Na K, Li K, Fang L, Guo C, Wang X. Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation. Carbohydrate Polymers 2021;256:117594. [DOI: 10.1016/j.carbpol.2020.117594] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
311 Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials 2019;84:105803. [PMID: 31260793 DOI: 10.1016/j.cct.2019.06.017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 18.7] [Reference Citation Analysis]
312 Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) 2016;95:e3887. [PMID: 27281105 DOI: 10.1097/MD.0000000000003887] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 8.2] [Reference Citation Analysis]
313 Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471-479. [PMID: 22962039 DOI: 10.1111/j.2047-6310.2012.00082.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
314 Liu D, Wong CC, Zhou Y, Li C, Chen H, Ji F, Go MYY, Wang F, Su H, Wei H, Cai Z, Wong N, Wong VWS, Yu J. Squalene Epoxidase Induces Nonalcoholic Steatohepatitis Via Binding to Carbonic Anhydrase III and is a Therapeutic Target. Gastroenterology 2021;160:2467-2482.e3. [PMID: 33647280 DOI: 10.1053/j.gastro.2021.02.051] [Reference Citation Analysis]
315 Morrison MC, Kleemann R, van Koppen A, Hanemaaijer R, Verschuren L. Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study. Front Physiol 2018;9:132. [PMID: 29527177 DOI: 10.3389/fphys.2018.00132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
316 Lingvay I, Raskin P, Szczepaniak LS. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007;21:137-42. [PMID: 17493545 DOI: 10.1016/j.jdiacomp.2007.02.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
317 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
318 Motawea A, Ahmed DAM, Eladl AS, El-Mansy AAE, Saleh NM. Appraisal of amiodarone-loaded PLGA nanoparticles for prospective safety and toxicity in a rat model. Life Sci 2021;274:119344. [PMID: 33716062 DOI: 10.1016/j.lfs.2021.119344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
319 Zhang P, Cheng X, Sun H, Li Y, Mei W, Zeng C. Atractyloside Protect Mice Against Liver Steatosis by Activation of Autophagy via ANT-AMPK-mTORC1 Signaling Pathway. Front Pharmacol 2021;12:736655. [PMID: 34621170 DOI: 10.3389/fphar.2021.736655] [Reference Citation Analysis]
320 Kim HY, Ahn SB, Hong JM, Oh JH, Saeed WK, Kim GS, Kim H, Kang JK, Kang S, Jun DW. BTT-105 ameliorates hepatic fibrosis in non-alcoholic fatty liver animal model. FASEB J 2021;35:e21979. [PMID: 34694029 DOI: 10.1096/fj.202002656RRR] [Reference Citation Analysis]
321 Hülser ML, Luo Y, Frommer K, Hasseli R, Köhler K, Diller M, Van Nie L, Rummel C, Roderfeld M, Roeb E, Schett G, Bozec A, Müller-Ladner U, Neumann E. Systemic versus local adipokine expression differs in a combined obesity and osteoarthritis mouse model. Sci Rep 2021;11:17001. [PMID: 34417537 DOI: 10.1038/s41598-021-96545-8] [Reference Citation Analysis]
322 Hardy T, Wonders K, Younes R, Aithal GP, Aller R, Allison M, Bedossa P, Betsou F, Boursier J, Brosnan MJ, Burt A, Cobbold J, Cortez-Pinto H, Day CP, Dufour JF, Ekstedt M, Francque S, Harrison S, Miele L, Nasr P, Papatheodoridis G, Petta S, Tiniakos D, Torstenson R, Valenti L, Holleboom AG, Yki-Jarvinen H, Geier A, Romero-Gomez M, Ratziu V, Bugianesi E, Schattenberg JM, Anstee QM; LITMUS Consortium. The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemp Clin Trials 2020;98:106175. [PMID: 33045403 DOI: 10.1016/j.cct.2020.106175] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
323 Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020;11:40-7. [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
324 Ogrodnik M, Miwa S, Tchkonia T, Tiniakos D, Wilson CL, Lahat A, Day CP, Burt A, Palmer A, Anstee QM, Grellscheid SN, Hoeijmakers JHJ, Barnhoorn S, Mann DA, Bird TG, Vermeij WP, Kirkland JL, Passos JF, von Zglinicki T, Jurk D. Cellular senescence drives age-dependent hepatic steatosis. Nat Commun 2017;8:15691. [PMID: 28608850 DOI: 10.1038/ncomms15691] [Cited by in Crossref: 325] [Cited by in F6Publishing: 313] [Article Influence: 65.0] [Reference Citation Analysis]
325 Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? European Journal of Internal Medicine 2017;46:1-5. [DOI: 10.1016/j.ejim.2017.06.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
326 Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, Diehl AM, Djedjos CS, Han L, Myers RP. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2017;. [PMID: 28892558 DOI: 10.1002/hep.29514.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
327 Zhang C, Wang G, Zheng Z, Maddipati KR, Zhang X, Dyson G, Williams P, Duncan SA, Kaufman RJ, Zhang K. Endoplasmic reticulum-tethered transcription factor cAMP responsive element-binding protein, hepatocyte specific, regulates hepatic lipogenesis, fatty acid oxidation, and lipolysis upon metabolic stress in mice. Hepatology 2012;55:1070-82. [PMID: 22095841 DOI: 10.1002/hep.24783] [Cited by in Crossref: 125] [Cited by in F6Publishing: 127] [Article Influence: 12.5] [Reference Citation Analysis]
328 Corbin KD, Abdelmalek MF, Spencer MD, da Costa KA, Galanko JA, Sha W, Suzuki A, Guy CD, Cardona DM, Torquati A, Diehl AM, Zeisel SH. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J 2013;27:1674-89. [PMID: 23292069 DOI: 10.1096/fj.12-219097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
329 Park YS, Park SH, Lee SS, Kim DY, Shin YM, Lee W, Lee SG, Yu ES. Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology. 2011;258:760-766. [PMID: 21212369 DOI: 10.1148/radiol.10101233] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
330 Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:117-23. [PMID: 31523999 DOI: 10.1080/13543784.2020.1668375] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
331 Asimakopoulou A, Fülöp A, Borkham-Kamphorst E, de Leur EV, Gassler N, Berger T, Beine B, Meyer HE, Mak TW, Hopf C, Henkel C, Weiskirchen R. Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis. Biochim Biophys Acta Mol Basis Dis 2017;1863:2093-110. [PMID: 28396286 DOI: 10.1016/j.bbadis.2017.04.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
332 Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration. Scandinavian Journal of Clinical and Laboratory Investigation 2011;71:631-6. [DOI: 10.3109/00365513.2011.604427] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
333 Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca JR, Yost RA, Cusi K, Garrett TJ, Sunny NE. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am J Physiol Endocrinol Metab. 2016;310:E484-E494. [PMID: 26814015 DOI: 10.1152/ajpendo.00492.2015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 11.5] [Reference Citation Analysis]
334 Verveer C, Zondervan PE, ten Kate FJ, Hansen BE, Janssen HL, de Knegt RJ. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int. 2012;32:622-628. [PMID: 22098684 DOI: 10.1111/j.1478-3231.2011.02663.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
335 Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18:847-853. [PMID: 18459024 DOI: 10.1007/s11695-007-9355-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
336 Li X, Zeng F, Huang Y, Liu B. The Positive Effects of Grifola frondosa Heteropolysaccharide on NAFLD and Regulation of the Gut Microbiota. Int J Mol Sci 2019;20:E5302. [PMID: 31653116 DOI: 10.3390/ijms20215302] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
337 Abo El-Magd NF, Ramadan NM, Eraky SM. The ameliorative effect of bromelain on STZ-induced type 1 diabetes in rats through Oxi-LDL/LPA/LPAR1 pathway. Life Sci 2021;285:119982. [PMID: 34592232 DOI: 10.1016/j.lfs.2021.119982] [Reference Citation Analysis]
338 Ma K, Chen Y, Liang X, Miao J, Zhao Q. Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model. Iran J Basic Med Sci 2017;20:1207-12. [PMID: 29299197 DOI: 10.22038/IJBMS.2017.9482] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
339 Moolla A, de Boer J, Pavlov D, Amin A, Taylor A, Gilligan L, Hughes B, Ryan J, Barnes E, Hassan-Smith Z, Grove J, Aithal GP, Verrijken A, Francque S, Van Gaal L, Armstrong MJ, Newsome PN, Cobbold JF, Arlt W, Biehl M, Tomlinson JW. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Aliment Pharmacol Ther 2020;51:1188-97. [PMID: 32298002 DOI: 10.1111/apt.15710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
340 Knebel C, Buhrke T, Süssmuth R, Lampen A, Marx-Stoelting P, Braeuning A. Pregnane X receptor mediates steatotic effects of propiconazole and tebuconazole in human liver cell lines. Arch Toxicol 2019;93:1311-22. [PMID: 30989312 DOI: 10.1007/s00204-019-02445-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
341 Hoang SA, Oseini A, Feaver RE, Cole BK, Asgharpour A, Vincent R, Siddiqui M, Lawson MJ, Day NC, Taylor JM, Wamhoff BR, Mirshahi F, Contos MJ, Idowu M, Sanyal AJ. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:12541. [PMID: 31467298 DOI: 10.1038/s41598-019-48746-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
342 Mitry RR, De Bruyne R, Quaglia A, Hughes RD, Dhawan A. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology 2007;46:2047-8; author reply 2048. [PMID: 18046726 DOI: 10.1002/hep.21998] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
343 Ye J, Lv L, Wu W, Li Y, Shi D, Fang D, Guo F, Jiang H, Yan R, Ye W, Li L. Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels. Front Microbiol. 2018;9:1967. [PMID: 30186272 DOI: 10.3389/fmicb.2018.01967] [Cited by in Crossref: 68] [Cited by in F6Publishing: 72] [Article Influence: 17.0] [Reference Citation Analysis]
344 McCulloch LJ, Bramwell LR, Knight B, Kos K. Circulating and tissue specific transcription of angiopoietin-like protein 4 in human Type 2 diabetes. Metabolism 2020;106:154192. [PMID: 32112823 DOI: 10.1016/j.metabol.2020.154192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
345 Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 2014;111:9983-8. [PMID: 24961373 DOI: 10.1073/pnas.1314939111] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 17.1] [Reference Citation Analysis]
346 Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92:713-723. [PMID: 22411067 DOI: 10.1038/labinvest.2012.45] [Cited by in Crossref: 92] [Cited by in F6Publishing: 95] [Article Influence: 9.2] [Reference Citation Analysis]
347 Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim 2019;68:147-58. [PMID: 30487357 DOI: 10.1538/expanim.18-0108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
348 Molla NW, Hassanain MM, Fadel Z, Boucher LM, Madkhali A, Altahan RM, Alrijraji EA, Simoneau EB, Alamri H, Salman A. Effect of non-alcoholic liver disease on recurrence rate and liver regeneration after liver resection for colorectal liver metastases. Curr Oncol. 2017;24:e233-e243. [PMID: 28680292 DOI: 10.3747/co.24.3133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
349 Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Aishima S, Kage M, Itoh Y, Nakajima A, Eguchi Y. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol 2020;55:428-40. [PMID: 31654131 DOI: 10.1007/s00535-019-01635-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
350 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 20.8] [Reference Citation Analysis]
351 Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011;18:294-300. [PMID: 21654360 DOI: 10.1097/PAP.0b013e318220f59b] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
352 Moslehi A, Farahabadi M, Chavoshzadeh SA, Barati A, Ababzadeh S, Mohammadbeigi A. The Effect of Amygdalin on Endoplasmic Reticulum (ER) Stress Induced Hepatic Steatosis in Mice. Malays J Med Sci 2018;25:16-23. [PMID: 29599631 DOI: 10.21315/mjms2018.25.1.3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
353 Jiménez R, Hijona E, Emparanza J, Alústiza JM, Hijona L, Macarulla MT, Portillo MP, Herreros-Villanueva M, Beguiristain A, Arenas J, Bujanda L. Effect of neoadjuvant chemotherapy in hepatic steatosis. Chemotherapy 2012;58:89-94. [PMID: 22377819 DOI: 10.1159/000336133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
354 Rogers AB. Stress of Strains: Inbred Mice in Liver Research. Gene Expr 2018;19:61-7. [PMID: 30092856 DOI: 10.3727/105221618X15337408678723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
355 Hammoud RU, Jabbour MN, Tawil AN, Ghattas H, Obeid OA. Phosphorus Supplementation Mitigated Food Intake and Growth of Rats Fed a Low-Protein Diet. Curr Dev Nutr 2017;1:e000943. [PMID: 29955716 DOI: 10.3945/cdn.117.000943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
356 Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013;48:1051-1060. [PMID: 23184095 DOI: 10.1007/s00535-012-0704-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
357 Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol 2018;53:438-48. [PMID: 28744823 DOI: 10.1007/s00535-017-1372-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
358 Nguyen TN, Podkowa AS, Tam AY, Arnold EC, Miller RJ, Park TH, Do MN, Oelze ML. Characterizing Fatty Liver in vivo in Rabbits, Using Quantitative Ultrasound. Ultrasound Med Biol 2019;45:2049-62. [PMID: 31076231 DOI: 10.1016/j.ultrasmedbio.2019.03.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
359 Pastore A, Panera N, Mosca A, Caccamo R, Camanni D, Crudele A, De Stefanis C, Alterio A, Di Giovamberardino G, De Vito R, Francalanci P, Battaglia S, Muda AO, De Peppo F, Alisi A. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease. Obes Surg 2021. [PMID: 34546515 DOI: 10.1007/s11695-021-05701-6] [Reference Citation Analysis]
360 Alisi A, Bedogni G, De Vito R, Comparcola D, Manco M, Nobili V. Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. Digestive and Liver Disease 2011;43:143-6. [DOI: 10.1016/j.dld.2010.05.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
361 Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Blanco CDV, Federico A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine 2012;52:1658-65. [DOI: 10.1016/j.freeradbiomed.2012.02.008] [Cited by in Crossref: 135] [Cited by in F6Publishing: 122] [Article Influence: 13.5] [Reference Citation Analysis]
362 Tashiro H, Kuroda S, Mikuriya Y, Ohdan H. Ischemia-reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery. Surg Today. 2014;44:1611-1625. [PMID: 24078000 DOI: 10.1007/s00595-013-0736-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
363 Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Bello BD, Filice G, Filice C. Point shear wave elastography method for assessing liver stiffness. World J Gastroenterol 2014; 20(16): 4787-4796 [PMID: 24782633 DOI: 10.3748/wjg.v20.i16.4787] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 72] [Article Influence: 10.8] [Reference Citation Analysis]
364 Carotti S, Lettieri-Barbato D, Piemonte F, Ruggiero S, Rosina M, Zalfa F, Zingariello M, Arciprete F, Valentini F, Francesconi M, D'Amico J, De Vincentis A, Baiocchini A, Perrone G, Antonelli-Incalzi R, Morini S, Picardi A, Aquilano K, Vespasiani-Gentilucci U. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver. Cell Death Dis 2021;12:1092. [PMID: 34795230 DOI: 10.1038/s41419-021-04382-4] [Reference Citation Analysis]
365 Cassard-doulcier A, Perlemuter G. Inflammation hépatique liée à l’obésité (NASH). OCL 2011;18:21-6. [DOI: 10.1051/ocl.2011.0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
366 Sato T, Tsuchiya A, Owaki T, Kumagai M, Motegi S, Iwasawa T, Nojiri S, Ogawa M, Takeuchi S, Watanabe Y, Kawata Y, Kamimura H, Terai S. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;566:36-44. [PMID: 34116355 DOI: 10.1016/j.bbrc.2021.05.097] [Reference Citation Analysis]
367 Karlsson M, Ekstedt M, Dahlström N, Forsgren MF, Ignatova S, Norén B, Dahlqvist Leinhard O, Kechagias S, Lundberg P. Liver R2* is affected by both iron and fat: A dual biopsy-validated study of chronic liver disease. J Magn Reson Imaging 2019;50:325-33. [PMID: 30637926 DOI: 10.1002/jmri.26601] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
368 Tan C, Al-kalifah N, Lee W, Ser K, Lee Y, Chen J. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis. Asian Journal of Surgery 2019;42:203-8. [DOI: 10.1016/j.asjsur.2018.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
369 Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, Foti M, Nuoffer JM, St-Pierre MV, Dufour JF. Exercise Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation in Mice. Cancers (Basel) 2020;12:E1407. [PMID: 32486073 DOI: 10.3390/cancers12061407] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
370 Steffensen IL, Dirven H, Couderq S, David A, D'Cruz SC, Fernández MF, Mustieles V, Rodríguez-Carrillo A, Hofer T. Bisphenols and Oxidative Stress Biomarkers-Associations Found in Human Studies, Evaluation of Methods Used, and Strengths and Weaknesses of the Biomarkers. Int J Environ Res Public Health 2020;17:E3609. [PMID: 32455625 DOI: 10.3390/ijerph17103609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
371 França LM, Freitas LN, Chagas VT, Coêlho CF, Barroso WA, Costa GC, Silva LA, Debbas V, Laurindo FR, Paes AM. Mechanisms underlying hypertriglyceridemia in rats with monosodium L-glutamate-induced obesity: evidence of XBP-1/PDI/MTP axis activation. Biochem Biophys Res Commun 2014;443:725-30. [PMID: 24333444 DOI: 10.1016/j.bbrc.2013.12.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
372 Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, Al-Mdani AS, Al-Akwaa A, Almutharea S, Khan MQ, Alghamdi AS, Farah T, Al-Hamoudi W, Saadeh M, Abdo AA. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. J Viral Hepat 2011;18:e217-25. [PMID: 21692936 DOI: 10.1111/j.1365-2893.2011.01437.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
373 Moreno-navarrete JM, Touskova V, Sabater M, Mraz M, Drapalova J, Ortega F, Serrano M, Catalán V, Gómez-ambrosi J, Ortiz MR, Pardo G, Pueyo N, Ricart W, Lacinova Z, Haluzik M, Frühbeck G, Fernández-real JM. Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance. Int J Obes 2013;37:1230-7. [DOI: 10.1038/ijo.2012.223] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
374 Mitra A, Satelli A, Yan J, Xueqing X, Gagea M, Hunter CA, Mishra L, Li S. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology. 2014;60:2027-2039. [PMID: 25351459 DOI: 10.1002/hep.27392] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 7.8] [Reference Citation Analysis]
375 Fourman LT, Stanley TL, Billingsley JM, Sui SJH, Feldpausch MN, Boutin A, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep 2021;11:10485. [PMID: 34006921 DOI: 10.1038/s41598-021-89966-y] [Reference Citation Analysis]
376 Haas JT, Vonghia L, Mogilenko DA, Verrijken A, Molendi-Coste O, Fleury S, Deprince A, Nikitin A, Woitrain E, Ducrocq-Geoffroy L, Pic S, Derudas B, Dehondt H, Gheeraert C, Van Gaal L, Driessen A, Lefebvre P, Staels B, Francque S, Dombrowicz D. Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution. Nat Metab 2019;1:604-14. [PMID: 31701087 DOI: 10.1038/s42255-019-0076-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
377 Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182-187. [PMID: 23059409 DOI: 10.1097/mcg.0b013e318264181d] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 5.9] [Reference Citation Analysis]
378 Dowman JK, Hopkins LJ, Reynolds GM, Nikolaou N, Armstrong MJ, Shaw JC, Houlihan DD, Lalor PF, Tomlinson JW, Hübscher SG. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol. 2014;184:1550-1561. [PMID: 24650559 DOI: 10.1016/j.ajpath.2014.01.034] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
379 Arman T, Lynch KD, Montonye ML, Goedken M, Clarke JD. Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats. Toxins (Basel) 2019;11:E398. [PMID: 31323923 DOI: 10.3390/toxins11070398] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
380 Martín-castillo A, Castells MT, Adánez G, Polo MTS, Pérez BG, Ayala I. Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens. Biomedicine & Pharmacotherapy 2010;64:275-81. [DOI: 10.1016/j.biopha.2009.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
381 El-Koofy NM, Anwar GM, El-Raziky MS, El-Hennawy AM, El-Mougy FM, El-Karaksy HM, Hassanin FM, Helmy HM. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children. Saudi J Gastroenterol. 2012;18:44-49. [PMID: 22249092 DOI: 10.4103/1319-3767.91738] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
382 De Voogd FA, Mookhoek A, Gecse KB, De Hertogh G, Bemelman WA, Buskens CJ, D'Haens GR. Systematic Review: Histological Scoring of Strictures in Crohn's Disease. J Crohns Colitis 2020;14:734-42. [PMID: 32645156 DOI: 10.1093/ecco-jcc/jjz177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
383 Leong WL, Lai LL, Nik Mustapha NR, Vijayananthan A, Rahmat K, Mahadeva S, Chan WK. Comparing point shear wave elastography (ElastPQ) and transient elastography for diagnosis of fibrosis stage in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:135-41. [PMID: 31310032 DOI: 10.1111/jgh.14782] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
384 Shibata S, Joshita S, Umemura T, Yamazaki T, Fujimori N, Ichikawa Y, Komatsu M, Matsumoto A, Tanaka E. Liver stiffness-spleen size-to-platelet ratio risk score detects esophageal varices in chronic liver disease. Springerplus 2016;5:998. [PMID: 27398275 DOI: 10.1186/s40064-016-2708-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
385 Enomoto M, Ikura Y, Tamori A, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Murakami Y, Kawada N. Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C. United European Gastroenterol J 2018;6:1391-400. [PMID: 30386612 DOI: 10.1177/2050640618791053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
386 Sociali G, Magnone M, Ravera S, Damonte P, Vigliarolo T, Von Holtey M, Vellone VG, Millo E, Caffa I, Cea M, Parenti MD, Del Rio A, Murone M, Mostoslavsky R, Grozio A, Nencioni A, Bruzzone S. Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model. FASEB J 2017;31:3138-49. [PMID: 28386046 DOI: 10.1096/fj.201601294R] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
387 Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med 2016;279:485-93. [PMID: 26728692 DOI: 10.1111/joim.12462] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
388 Puri P, Sanyal AJ. Nonalcoholic fatty liver disease: Definitions, risk factors, and workup.Clin Liver Dis (Hoboken). 2012;1:99-103. [PMID: 31186860 DOI: 10.1002/cld.81] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
389 Langford CR, Goldinger MH, Treanor D, McGenity C, Dillman JR, Allende DS, Goldin R, Brunt EM, Zatloukal K, Denk H, Fleming KA. Improved pathology reporting in NAFLD/NASH for clinical trials. J Clin Pathol 2021:jclinpath-2021-207967. [PMID: 34753791 DOI: 10.1136/jclinpath-2021-207967] [Reference Citation Analysis]
390 Fitzpatrick E, Dhawan A. Childhood and Adolescent Nonalcoholic Fatty Liver Disease: Is It Different from Adults? J Clin Exp Hepatol 2019;9:716-22. [PMID: 31889753 DOI: 10.1016/j.jceh.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
391 Lecoutre S, Montel V, Vallez E, Pourpe C, Delmont A, Eury E, Verbanck M, Dickes-Coopman A, Daubersies P, Lesage J, Laborie C, Tailleux A, Staels B, Froguel P, Breton C, Vieau D. Transcription profiling in the liver of undernourished male rat offspring reveals altered lipid metabolism pathways and predisposition to hepatic steatosis. Am J Physiol Endocrinol Metab 2019;317:E1094-107. [PMID: 31638854 DOI: 10.1152/ajpendo.00291.2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
392 Arienti V, Aluigi L, Pretolani S, Accogli E, Polimeni L, Domanico A, Violi F. Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). Intern Emerg Med. 2012;7 Suppl 3:S283-S290. [PMID: 23073869 DOI: 10.1007/s11739-012-0824-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
393 Deng Z, Gao S, An Y, Huang Y, Liu H, Zhu W, Lu W, He M, Xie W, Yu D, Li Y. Effects of earthworm extract on the lipid profile and fatty liver induced by a high-fat diet in guinea pigs. Ann Transl Med 2021;9:292. [PMID: 33708919 DOI: 10.21037/atm-20-5362] [Reference Citation Analysis]
394 Hu DS, Zhu SH, Liu WY, Pan XY, Zhu PW, Li YY, Zheng KI, Ma HL, You J, Targher G, Byrne CD, Chen YP, Zheng MH. PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab 2020;46:496-503. [PMID: 32035968 DOI: 10.1016/j.diabet.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
395 Starmann J, Fälth M, Spindelböck W, Lanz KL, Lackner C, Zatloukal K, Trauner M, Sültmann H. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One. 2012;7:e46584. [PMID: 23071592 DOI: 10.1371/journal.pone.0046584] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 6.6] [Reference Citation Analysis]
396 Jamialahmadi O, Mancina RM, Ciociola E, Tavaglione F, Luukkonen PK, Baselli G, Malvestiti F, Thuillier D, Raverdy V, Männistö V, Pipitone RM, Pennisi G, Prati D, Spagnuolo R, Petta S, Pihlajamäki J, Pattou F, Yki-Järvinen H, Valenti L, Romeo S. Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology 2021;160:1634-1646.e7. [PMID: 33347879 DOI: 10.1053/j.gastro.2020.12.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
397 Ye D, Zhang T, Lou G, Xu W, Dong F, Chen G, Liu Y. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. Life Sci 2018;208:201-7. [PMID: 30030064 DOI: 10.1016/j.lfs.2018.07.029] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
398 Pais P, D'Amato M. In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitis. Drugs R D 2014;14:291-9. [PMID: 25404123 DOI: 10.1007/s40268-014-0068-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
399 Mastrocola R, Collino M, Rogazzo M, Medana C, Nigro D, Boccuzzi G, Aragno M. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol. 2013;305:G398-G407. [PMID: 23868406 DOI: 10.1152/ajpgi.00450.2012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
400 Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2017;15:1461-8. [PMID: 28479500 DOI: 10.1016/j.cgh.2017.04.040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
401 Kakehashi A, Chariyakornkul A, Suzuki S, Khuanphram N, Tatsumi K, Yamano S, Fujioka M, Gi M, Wongpoomchai R, Wanibuchi H. Cache Domain Containing 1 Is a Novel Marker of Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis. Cancers (Basel) 2021;13:1216. [PMID: 33802238 DOI: 10.3390/cancers13061216] [Reference Citation Analysis]
402 Zhang L, Wang P, Shi M, Fang Z, Ji J, Liao X, Hu X, Chen F. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis. The Journal of Nutritional Biochemistry 2020;80:108365. [DOI: 10.1016/j.jnutbio.2020.108365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
403 [DOI: 10.1101/2020.04.07.024455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
404 Forsgren MF, Nasr P, Karlsson M, Dahlström N, Norén B, Ignatova S, Sinkus R, Cedersund G, Leinhard OD, Ekstedt M, Kechagias S, Lundberg P. Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scand J Gastroenterol 2020;55:848-59. [PMID: 32684060 DOI: 10.1080/00365521.2020.1786599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
405 Orlicky DJ, Libby AE, Bales ES, McMahan RH, Monks J, La Rosa FG, McManaman JL. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions. J Physiol 2019;597:1565-84. [PMID: 30536914 DOI: 10.1113/JP277140] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
406 Kukla M, Zalewska-Ziob M, Adamek B, Kasperczyk J, Bułdak RJ, Sawczyn T, Stygar D, Sobala-Szczygieł B, Stachowska M, Gabriel A, Wiczkowski A. Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C. Clin Exp Hepatol 2019;5:147-54. [PMID: 31501791 DOI: 10.5114/ceh.2019.85074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
407 Evers DJ, Westerkamp AC, Spliethoff JW, Pully VV, Hompes D, Hendriks BHW, Prevoo W, van Velthuysen MF, Porte RJ, Ruers TJM. Diffuse reflectance spectroscopy: toward real-time quantification of steatosis in liver. Transpl Int 2015;28:465-74. [DOI: 10.1111/tri.12517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
408 Balampanis K, Chasapi A, Kourea E, Tanoglidi A, Hatziagelaki E, Lambadiari V, Dimitriadis G, Lambrou GI, Kalfarentzos F, Melachrinou M, Sotiropoulou-Bonikou G. Inter-tissue expression patterns of the key metabolic biomarker PGC-1α in severely obese individuals: Implication in obesity-induced disease. Hellenic J Cardiol 2019;60:282-93. [PMID: 30138744 DOI: 10.1016/j.hjc.2018.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
409 Roh YS, Kim JW, Park S, Shon C, Kim S, Eo SK, Kwon JK, Lim CW, Kim B. Toll-Like Receptor-7 Signaling Promotes Nonalcoholic Steatohepatitis by Inhibiting Regulatory T Cells in Mice. The American Journal of Pathology 2018;188:2574-88. [DOI: 10.1016/j.ajpath.2018.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
410 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
411 Shi T, Wu L, Ma W, Ju L, Bai M, Chen X, Liu S, Yang X, Shi J. Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evid Based Complement Alternat Med 2020;2020:8749564. [PMID: 31998400 DOI: 10.1155/2020/8749564] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
412 Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Kaneko S. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0191026. [PMID: 29342182 DOI: 10.1371/journal.pone.0191026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
413 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
414 Zhu C, Kim K, Wang X, Bartolome A, Salomao M, Dongiovanni P, Meroni M, Graham MJ, Yates KP, Diehl AM, Schwabe RF, Tabas I, Valenti L, Lavine JE, Pajvani UB. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci Transl Med 2018;10:eaat0344. [PMID: 30463916 DOI: 10.1126/scitranslmed.aat0344] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 18.0] [Reference Citation Analysis]
415 Qian LL, Wu L, Zhang L, Zhang J, Zhou J, Li YH, Fang QC, Li HT, Jia WP. Serum biomarkers combined with ultrasonography for early diagnosis of non-alcoholic fatty liver disease confirmed by magnetic resonance spectroscopy. Acta Pharmacol Sin 2020;41:554-60. [PMID: 31776449 DOI: 10.1038/s41401-019-0321-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
416 Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Intern Med 2020;59:1931-7. [PMID: 32448832 DOI: 10.2169/internalmedicine.4398-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
417 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, Tuncer I, Dolar E. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver. 2014;8:313-317. [PMID: 24827629 DOI: 10.5009/gnl.2014.8.3.313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
419 Levene AP, Goldin RD. Physiological hepatic nuclear vacuolation--how long does it persist? Histopathology 2010;56:426-9. [PMID: 20459549 DOI: 10.1111/j.1365-2559.2010.03501.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
420 De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, Candelaresi C, Giaccari A, Trozzi L, Pierantonelli I, Mingarelli E. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLoS One. 2014;9:e97136. [PMID: 24853141 DOI: 10.1371/journal.pone.0097136] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
421 Kheder R, Hobkirk J, Saeed Z, Janus J, Carroll S, Browning MJ, Stover C. Vitamin D3 supplementation of a high fat high sugar diet ameliorates prediabetic phenotype in female LDLR-/- and LDLR+/+ mice. Immun Inflamm Dis 2017;5:151-62. [PMID: 28474500 DOI: 10.1002/iid3.154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
422 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
423 Zhao Q, Wei M, Zhang S, Huang Z, Lu B, Ji L. The water extract of Sophorae tonkinensis Radix et Rhizoma alleviates non-alcoholic fatty liver disease and its mechanism. Phytomedicine 2020;77:153270. [PMID: 32702591 DOI: 10.1016/j.phymed.2020.153270] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
424 Chang ML, Kuo CJ, Huang HC, Chu YY, Chiu CT. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity. PLoS One 2016;11:e0166712. [PMID: 27870883 DOI: 10.1371/journal.pone.0166712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
425 Wang C, Tao Q, Wang X, Wang X, Zhang X. Impact of high-fat diet on liver genes expression profiles in mice model of nonalcoholic fatty liver disease. Environ Toxicol Pharmacol 2016;45:52-62. [PMID: 27262986 DOI: 10.1016/j.etap.2016.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
426 Paradis V, Bedossa P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes & Metabolism 2008;34:638-42. [DOI: 10.1016/s1262-3636(08)74598-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
427 Taniai M, Hashimoto E, Tobari M, Yatsuji S, Haruta I, Tokushige K, Shiratori K. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol Res 2009;39:685-93. [PMID: 19473432 DOI: 10.1111/j.1872-034X.2009.00507.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
428 Rezende AQM, Gestic MA, Utrini MP, Chaim FDM, Saito HPA, Chaim EA, Callejas-Neto F, Cazzo E. Is there a link between non-alcoholic fatty liver disease aspects and pancreatic cancer? Results of a case-matched study. Rev Col Bras Cir 2021;48:e20202913. [PMID: 34259747 DOI: 10.1590/0100-6991e-20202913] [Reference Citation Analysis]
429 Vilar L, Oliveira CP, Faintuch J, Mello ES, Nogueira MA, Santos TE, Alves VA, Carrilho FJ. High-fat diet: a trigger of non-alcoholic steatohepatitis? Preliminary findings in obese subjects. Nutrition. 2008;24:1097-1102. [PMID: 18640006 DOI: 10.1016/j.nut.2008.05.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
430 Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015;27:1154-1160. [PMID: 26148245 DOI: 10.1097/meg.0000000000000421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
431 Alizai PH, Wendl J, Roeth AA, Klink CD, Luedde T, Steinhoff I, Neumann UP, Schmeding M, Ulmer F. Functional Liver Recovery After Bariatric Surgery--a Prospective Cohort Study with the LiMAx Test. Obes Surg. 2015;25:2047-2053. [PMID: 25869925 DOI: 10.1007/s11695-015-1664-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
432 Bhadoria AS, Kedarisetty CK, Bihari C, Kumar G, Jindal A, Bhardwaj A, Shasthry V, Vyas T, Benjamin J, Sharma S. Impact of family history of metabolic traits on severity of non-alcoholic steatohepatitis related cirrhosis: A cross-sectional study. Liver Int. 2017;37:1397-1404. [PMID: 28231412 DOI: 10.1111/liv.13396] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
433 Ergelen R, Akyuz U, Aydin Y, Eren F, Yilmaz Y. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2015;27:667-71. [DOI: 10.1097/meg.0000000000000342] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
434 Asaoka Y, Terai S, Sakaida I, Nishina H. The expanding role of fish models in understanding non-alcoholic fatty liver disease. Dis Model Mech. 2013;6:905-914. [PMID: 23720231 DOI: 10.1242/dmm.011981] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
435 Koncsos G, Varga ZV, Baranyai T, Boengler K, Rohrbach S, Li L, Schlüter KD, Schreckenberg R, Radovits T, Oláh A, Mátyás C, Lux Á, Al-Khrasani M, Komlódi T, Bukosza N, Máthé D, Deres L, Barteková M, Rajtík T, Adameová A, Szigeti K, Hamar P, Helyes Z, Tretter L, Pacher P, Merkely B, Giricz Z, Schulz R, Ferdinandy P. Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol 2016;311:H927-43. [PMID: 27521417 DOI: 10.1152/ajpheart.00049.2016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 6.5] [Reference Citation Analysis]
436 Pruis MG, Lendvai A, Bloks VW, Zwier MV, Baller JF, de Bruin A, Groen AK, Plösch T. Maternal western diet primes non-alcoholic fatty liver disease in adult mouse offspring. Acta Physiol (Oxf). 2014;210:215-227. [PMID: 24224789 DOI: 10.1111/apha.12197] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
437 Sheldon RD, Meers GM, Morris EM, Linden MA, Cunningham RP, Ibdah JA, Thyfault JP, Laughlin MH, Rector RS. eNOS deletion impairs mitochondrial quality control and exacerbates Western diet-induced NASH. Am J Physiol Endocrinol Metab 2019;317:E605-16. [PMID: 31361543 DOI: 10.1152/ajpendo.00096.2019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
438 França LM, Coêlho CFF, Freitas LNC, Souza ILS, Chagas VT, Debbas V, de Lima TM, de Souza HP, Laurindo FRM, Paes AMA. Syzygium cumini Leaf Extract Reverts Hypertriglyceridemia via Downregulation of the Hepatic XBP-1s/PDI/MTP Axis in Monosodium L-Glutamate-Induced Obese Rats. Oxid Med Cell Longev 2019;2019:9417498. [PMID: 31015892 DOI: 10.1155/2019/9417498] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
439 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
440 Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 2020;65:623-31. [PMID: 30684076 DOI: 10.1007/s10620-019-5477-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
441 Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Abdalla MA, Akhlaghi S, Sathyapalan T, Sahebkar A. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery. Eat Weight Disord 2021. [PMID: 33999371 DOI: 10.1007/s40519-021-01151-2] [Reference Citation Analysis]
442 David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:1904-1912. [PMID: 19434741 DOI: 10.1002/hep.22868] [Cited by in Crossref: 85] [Cited by in F6Publishing: 84] [Article Influence: 6.5] [Reference Citation Analysis]
443 Itagaki H, Shimizu K, Morikawa S, Ogawa K, Ezaki T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice. Int J Clin Exp Pathol. 2013;6:2683-2696. [PMID: 24294355 DOI: 10.1155/2013/527548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
444 Feng Q, Gou XJ, Meng SX, Huang C, Zhang YQ, Tang YJ, Wang WJ, Xu L, Peng JH, Hu YY. Qushi Huayu Decoction Inhibits Hepatic Lipid Accumulation by Activating AMP-Activated Protein Kinase In Vivo and In Vitro. Evid Based Complement Alternat Med 2013;2013:184358. [PMID: 23573117 DOI: 10.1155/2013/184358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
445 Cabré N, Luciano-Mateo F, Fernández-Arroyo S, Baiges-Gayà G, Hernández-Aguilera A, Fibla M, Fernández-Julià R, París M, Sabench F, Castillo DD, Menéndez JA, Camps J, Joven J. Laparoscopic sleeve gastrectomy reverses non-alcoholic fatty liver disease modulating oxidative stress and inflammation. Metabolism 2019;99:81-9. [PMID: 31279739 DOI: 10.1016/j.metabol.2019.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
446 Pandit H, Tinney JP, Li Y, Cui G, Li S, Keller BB, Martin RC. Utilizing Contrast-Enhanced Ultrasound Imaging for Evaluating Fatty Liver Disease Progression in Pre-clinical Mouse Models. Ultrasound in Medicine & Biology 2019;45:549-57. [DOI: 10.1016/j.ultrasmedbio.2018.10.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
447 Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One. 2012;7:e30325. [PMID: 22431959 DOI: 10.1371/journal.pone.0030325] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
448 Walker RW, Allayee H, Inserra A, Fruhwirth R, Alisi A, Devito R, Carey ME, Sinatra F, Goran MI, Nobili V. Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children. Obesity (Silver Spring). 2014;22:1512-1519. [PMID: 24616207 DOI: 10.1002/oby.20730] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
449 St-Jules DE, Watters CA, Nagamori K, King J. The effect of weight loss on pediatric nonalcoholic Fatty liver disease. ISRN Gastroenterol. 2013;2013:398297. [PMID: 23781345 DOI: 10.1155/2013/398297] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Allende DS, Gawrieh S, Cummings OW, Belt P, Wilson L, Van Natta M, Behling CA, Carpenter D, Gill RM, Kleiner DE, Yeh MM, Chalasani N, Guy CD; NASH Clinical Research Network. Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. Liver Int 2021;41:996-1011. [PMID: 33354866 DOI: 10.1111/liv.14773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
451 Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, Andris D, Makladi B, Cole R, Charlton M. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg. 2010;20:1698-1709. [PMID: 20473581 DOI: 10.1007/s11695-010-0171-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
452 Trout AT, Sheridan RM, Serai SD, Xanthakos SA, Su W, Zhang B, Wallihan DB. Diagnostic Performance of MR Elastography for Liver Fibrosis in Children and Young Adults with a Spectrum of Liver Diseases. Radiology. 2018;287:824-832. [PMID: 29470938 DOI: 10.1148/radiol.2018172099] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
453 Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, Hou J, Belt PH, Kohil R, Lavine JE, Molleston JP, Newton KP, Whitington PF, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network. In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. Clin Gastroenterol Hepatol 2018;16:438-446.e1. [PMID: 28286193 DOI: 10.1016/j.cgh.2017.02.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
454 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
455 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe. 2010;31:225-237. [PMID: 20221762 DOI: 10.1007/s00292-010-1298-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
456 Karimi-Sales E, Ebrahimi-Kalan A, Alipour MR. Preventive effect of trans-chalcone on non-alcoholic steatohepatitis: Improvement of hepatic lipid metabolism. Biomed Pharmacother 2019;109:1306-12. [PMID: 30551380 DOI: 10.1016/j.biopha.2018.10.196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
457 Li WC, Zhao SX, Ren WG, Zhang YG, Wang RQ, Kong LB, Zhang QS, Nan YM. Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice. Exp Ther Med 2021;22:830. [PMID: 34149876 DOI: 10.3892/etm.2021.10262] [Reference Citation Analysis]
458 Moon S, Chung GE, Joo SK, Park JH, Chang MS, Yoon JW, Koo BK, Kim W. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00472-9. [PMID: 33905771 DOI: 10.1016/j.cgh.2021.04.038] [Reference Citation Analysis]
459 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
460 Celikbilek M, Gürsoy S, Deniz K, Karaman A, Zararsiz G, Yurci A. Mean platelet volume in biopsy-proven non-alcoholic fatty liver disease. Platelets. 2013;24:194-199. [PMID: 22646469 DOI: 10.3109/09537104.2012.688898] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
461 Luther J, Gala MK, Borren N, Masia R, Goodman RP, Moeller IH, DiGiacomo E, Ehrlich A, Warren A, Yarmush ML, Ananthakrishnan A, Corey K, Kaplan LM, Bhatia S, Chung RT, Patel SJ. Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity. Hepatol Commun 2018;2:786-97. [PMID: 30202815 DOI: 10.1002/hep4.1179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
462 Simpson AL, Doussot A, Creasy JM, Adams LB, Allen PJ, DeMatteo RP, Gönen M, Kemeny NE, Kingham TP, Shia J, Jarnagin WR, Do RKG, D'Angelica MI. Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Ann Surg Oncol 2017;24:2482-90. [PMID: 28560599 DOI: 10.1245/s10434-017-5896-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
463 Tanaka N, Horiuchi A, Yokoyama T, Kaneko G, Horigome N, Yamaura T, Nagaya T, Komatsu M, Sano K, Miyagawa S, Aoyama T, Tanaka E. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol. 2011;46:758-768. [PMID: 21267748 DOI: 10.1007/s00535-011-0370-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 6.1] [Reference Citation Analysis]
464 Agrawal S, Hoad CL, Francis ST, Guha IN, Kaye P, Aithal GP. Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scandinavian Journal of Gastroenterology 2017;52:107-15. [DOI: 10.1080/00365521.2016.1233578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
465 Kharbanda KK, Todero SL, Thomes PG, Orlicky DJ, Osna NA, French SW, Tuma DJ. Increased methylation demand exacerbates ethanol-induced liver injury. Exp Mol Pathol. 2014;97:49-56. [PMID: 24842317 DOI: 10.1016/j.yexmp.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
466 K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P. Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. Dig Liver Dis 2015;47:296-302. [PMID: 25596930 DOI: 10.1016/j.dld.2014.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
467 Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382-388. [PMID: 21448070 DOI: 10.1097/MEG.0b013e328345c8c7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
468 Thomsen KL, Hebbard L, Glavind E, Clouston A, Vilstrup H, George J, Grønbæk H. Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver Int 2014;34:1584-92. [PMID: 24674765 DOI: 10.1111/liv.12547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
469 Udompap P, Sukonrut K, Suvannarerg V, Pongpaibul A, Charatcharoenwitthaya P. Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4 for staging liver fibrosis in chronic viral hepatitis. J Viral Hepat 2020;27:437-48. [PMID: 31799740 DOI: 10.1111/jvh.13246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
470 Nalbantoglu IL, Tan BR Jr, Linehan DC, Gao F, Brunt EM. Histological features and severity of oxaliplatin-induced liver injury and clinical associations. J Dig Dis 2014;15:553-60. [PMID: 25060628 DOI: 10.1111/1751-2980.12177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
471 Alkhouri N, Eng K, Lopez R, Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD). Springerplus 2014;3:407. [PMID: 25126490 DOI: 10.1186/2193-1801-3-407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
472 Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels J, Zech F, Ceratti A, Gigot J. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 2010;147:185-94. [DOI: 10.1016/j.surg.2009.01.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
473 Xiong M, Huang Y, Liu Y, Huang M, Song G, Ming Q, Ma X, Yang J, Deng S, Wen Y, Shen J, Liu QH, Zhao P, Yang X. Antidiabetic Activity of Ergosterol from Pleurotus Ostreatus in KK-Ay Mice with Spontaneous Type 2 Diabetes Mellitus. Mol Nutr Food Res 2018;62. [PMID: 29080247 DOI: 10.1002/mnfr.201700444] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
474 González IA, Fuller LD, Zhang X, Papke DJ, Zhao L, Zhang D, Liao X, Liu X, Fiel MI, Zhang X. Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis. Am J Clin Pathol 2021:aqab142. [PMID: 34596220 DOI: 10.1093/ajcp/aqab142] [Reference Citation Analysis]
475 Ou H, Cai S, Liu Y, Xia M, Peng J. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therap Adv Gastroenterol 2017;10:207-17. [PMID: 28203279 DOI: 10.1177/1756283X16681707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
476 Morse CG, McLaughlin M, Proschan M, Koh C, Kleiner DE, Heller T, Kovacs JA. Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. AIDS 2015;29:2297-302. [PMID: 26544701 DOI: 10.1097/QAD.0000000000000841] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
477 Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883-1894. [PMID: 21381068 DOI: 10.1002/hep.24283] [Cited by in Crossref: 560] [Cited by in F6Publishing: 532] [Article Influence: 50.9] [Reference Citation Analysis]
478 Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, Rojano-Rodríguez ME, Quintero-Bustos G, Castro-Narro G, Moctezuma-Velazquez C. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value. Dig Dis Sci 2021. [PMID: 33428035 DOI: 10.1007/s10620-020-06821-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
479 Hoffmann C, Djerir NEH, Danckaert A, Fernandes J, Roux P, Charrueau C, Lachagès AM, Charlotte F, Brocheriou I, Clément K, Aron-Wisnewsky J, Foufelle F, Ratziu V, Hainque B, Bonnefont-Rousselot D, Bigey P, Escriou V. Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. Sci Rep 2020;10:3850. [PMID: 32123215 DOI: 10.1038/s41598-020-60615-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
480 Caviglia GP, Rosso C, Armandi A, Gaggini M, Carli F, Abate ML, Olivero A, Ribaldone DG, Saracco GM, Gastaldelli A, Bugianesi E. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. Int J Mol Sci 2020;21:E8838. [PMID: 33266488 DOI: 10.3390/ijms21228838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
481 Pérez-Martínez L, Ochoa-Callejero L, Rubio-Mediavilla S, Narro J, Bernardo I, Oteo JA, Blanco JR. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. Transl Res 2018;196:17-30. [PMID: 29421523 DOI: 10.1016/j.trsl.2018.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
482 Kuroda H, Kakisaka K, Kamiyama N, Oikawa T, Onodera M, Sawara K, Oikawa K, Endo R, Takikawa Y, Suzuki K. Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude. World J Gastroenterol 2012; 18(29): 3889-3895 [PMID: 22876042 DOI: 10.3748/wjg.v18.i29.3889] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
483 Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, Pareja MJ, Vilar-Gómez E, Caballería J, Escudero-García D, Gomez-Camarero J, Calleja JL, Latorre M, Albillos A, Salmeron J, Aspichueta P, Lo Iacono O, Francés R, Benlloch S, Fernández-Rodríguez C, García-Samaniego J, Estévez P, Andrade RJ, Turnes J, Romero-Gómez M; HEPAmet Registry. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther 2018;48:1260-70. [PMID: 30353552 DOI: 10.1111/apt.15015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
484 Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375-82. [PMID: 33037056 DOI: 10.1136/gutjnl-2020-322786] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
485 Teramoto T, Shinohara T, Takiyama A. Computer-aided classification of hepatocellular ballooning in liver biopsies from patients with NASH using persistent homology. Comput Methods Programs Biomed 2020;195:105614. [PMID: 32650090 DOI: 10.1016/j.cmpb.2020.105614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
486 Zhang Q, Xiang S, Liu Q, Gu T, Yao Y, Lu X. PPARγ Antagonizes Hypoxia-Induced Activation of Hepatic Stellate Cell through Cross Mediating PI3K/AKT and cGMP/PKG Signaling. PPAR Res 2018;2018:6970407. [PMID: 29686697 DOI: 10.1155/2018/6970407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
487 Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-1891. [PMID: 28774887 DOI: 10.1136/gutjnl-2017-314307] [Cited by in Crossref: 166] [Cited by in F6Publishing: 169] [Article Influence: 33.2] [Reference Citation Analysis]
488 Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59:30-43. [PMID: 26407715 DOI: 10.1007/s00125-015-3769-3] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 15.7] [Reference Citation Analysis]
489 Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, Cohen BL, Brenner D, Sirlin C, Loomba R; San Diego Integrated NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32. [PMID: 22431131 DOI: 10.1002/hep.25731] [Cited by in Crossref: 169] [Cited by in F6Publishing: 165] [Article Influence: 16.9] [Reference Citation Analysis]
490 Doherty Lyons S, Blum JL, Hoffman-Budde C, Tijerina PB, Fiel MI, J Conklin D, Gany F, Odin JA, Zelikoff JT. Prenatal Exposure to Gutkha, a Globally Relevant Smokeless Tobacco Product, Induces Hepatic Changes in Adult Mice. Int J Environ Res Public Health 2020;17:E7895. [PMID: 33126512 DOI: 10.3390/ijerph17217895] [Reference Citation Analysis]
491 Saldarriaga OA, Dye B, Pham J, Wanninger TG, Millian D, Kueht M, Freiberg B, Utay N, Stevenson HL. Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome. Sci Rep 2021;11:14506. [PMID: 34267267 DOI: 10.1038/s41598-021-93881-7] [Reference Citation Analysis]
492 Rezende RE, Duarte SM, Stefano JT, Roschel H, Gualano B, de Sá Pinto AL, Vezozzo DC, Carrilho FJ, Oliveira CP. Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. Menopause 2016;23:876-83. [PMID: 27458060 DOI: 10.1097/GME.0000000000000647] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 5.8] [Reference Citation Analysis]
493 Holterman AL, Holterman M, Browne A, Henriques S, Guzman G, Fantuzzi G. Patterns of surgical weight loss and resolution of metabolic abnormalities in superobese bariatric adolescents. Journal of Pediatric Surgery 2012;47:1633-9. [DOI: 10.1016/j.jpedsurg.2012.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
494 Wang Z, Li S, Wang R, Guo L, Xu D, Zhang T, Xu Y, Wang W, Wang M, Gan Z, Wang X. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD). Mol Med 2020;26:54. [PMID: 32503411 DOI: 10.1186/s10020-020-00164-4] [Reference Citation Analysis]
495 Moya M, Gómez-Lechón MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010;184:376-87. [PMID: 20079722 DOI: 10.1016/j.cbi.2010.01.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
496 Drescher HK, Schippers A, Rosenhain S, Gremse F, Bongiovanni L, Bruin A, Eswaran S, Gallage SU, Pfister D, Szydlowska M, Heikenwalder M, Weiskirchen S, Wagner N, Trautwein C, Weiskirchen R, Kroy DC. L-Selectin/CD62L is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men. Cells 2020;9:E1106. [PMID: 32365632 DOI: 10.3390/cells9051106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
497 Jia Y, Wu C, Kim J, Kim B, Lee S. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt. The Journal of Nutritional Biochemistry 2016;28:9-18. [DOI: 10.1016/j.jnutbio.2015.09.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 10.5] [Reference Citation Analysis]
498 Wang Y, Chen J, Kong W, Zhu R, Liang K, Kan Q, Lou Y, Liu X. Regulation of SIRT3/FOXO1 Signaling Pathway in Rats with Non-alcoholic Steatohepatitis by Salvianolic Acid B. Archives of Medical Research 2017;48:506-12. [DOI: 10.1016/j.arcmed.2017.11.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
499 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
500 Nakamura A, Yoneda M, Fujita K, Tajima K, Kikuchi K, Nakajima A, Maeda S, Terauchi Y. Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. J Diabetes Investig 2011;2:483-9. [PMID: 24843533 DOI: 10.1111/j.2040-1124.2011.00134.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
501 Yoshioka N, Tanaka M, Ochi K, Watanabe A, Ono K, Sawada M, Ogi T, Itoh M, Ito A, Shiraki Y, Enomoto A, Ishigami M, Fujishiro M, Ogawa Y, Suganami T. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. Biomed Pharmacother 2021;140:111738. [PMID: 34029949 DOI: 10.1016/j.biopha.2021.111738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72. [PMID: 19038040 DOI: 10.1186/1479-5876-6-72] [Cited by in Crossref: 47] [Cited by in F6Publishing: 58] [Article Influence: 3.4] [Reference Citation Analysis]
503 Kocabay G, Karabay CY, Colak Y, Oduncu V, Kalayci A, Akgun T, Guler A, Kirma C. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin Sci (Lond). 2014;126:297-304. [PMID: 23947743 DOI: 10.1042/cs20130298] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
504 Besutti G, Valenti L, Ligabue G, Bassi MC, Pattacini P, Guaraldi G, Giorgi Rossi P. Accuracy of imaging methods for steatohepatitis diagnosis in non‐alcoholic fatty liver disease patients: A systematic review. Liver Int 2019;39:1521-34. [DOI: 10.1111/liv.14118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
505 Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. [PMID: 26785389 DOI: 10.1111/hepr.12656] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 12.3] [Reference Citation Analysis]
506 Yeh MM. Nonalcoholic Fatty Liver Disease. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 435-40. [DOI: 10.1016/b978-0-443-06803-4.00031-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
507 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol 2020;11:609900. [PMID: 33574818 DOI: 10.3389/fimmu.2020.609900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
508 Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther 2007;26:821-30. [PMID: 17767466 DOI: 10.1111/j.1365-2036.2007.03425.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
509 Vilar-Gomez E, Calzadilla-Bertot L, Wong VW, Castellanos M, Aller-de la Fuente R, Eslam M, Wong GL, George J, Romero-Gomez M, Adams LA. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. Clin Gastroenterol Hepatol 2021;19:136-145.e6. [PMID: 32389886 DOI: 10.1016/j.cgh.2020.04.083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
510 Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. J Hepatol. 2018;68:238-250. [PMID: 29154966 DOI: 10.1016/j.jhep.2017.11.012] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 32.0] [Reference Citation Analysis]
511 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
512 Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, Louden C, Tio F, Cusi K. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54:837-845. [PMID: 21674556 DOI: 10.1002/hep.24483] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
513 Seillier M, Pouyet L, N'Guessan P, Nollet M, Capo F, Guillaumond F, Peyta L, Dumas JF, Varrault A, Bertrand G, Bonnafous S, Tran A, Meur G, Marchetti P, Ravier MA, Dalle S, Gual P, Muller D, Rutter GA, Servais S, Iovanna JL, Carrier A. Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1. EMBO Mol Med 2015;7:802-18. [PMID: 25828351 DOI: 10.15252/emmm.201404318] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
514 Dennis A, Mouchti S, Kelly M, Fallowfield JA, Hirschfield G, Pavlides M, Banerjee R. A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. Sci Rep 2020;10:15308. [PMID: 32943694 DOI: 10.1038/s41598-020-71995-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
515 Skat-Rørdam J, Ipsen DH, Seemann SE, Latta M, Lykkesfeldt J, Tveden-Nyborg P. Modelling Nonalcoholic Steatohepatitis In Vivo-A Close Transcriptomic Similarity Supports the Guinea Pig Disease Model. Biomedicines 2021;9:1198. [PMID: 34572384 DOI: 10.3390/biomedicines9091198] [Reference Citation Analysis]
516 Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther 2018;47:989-1000. [PMID: 29446106 DOI: 10.1111/apt.14529] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
517 Suzuki A, Kakisaka K, Suzuki Y, Wang T, Takikawa Y. c-Jun N-terminal kinase-mediated Rubicon expression enhances hepatocyte lipoapoptosis and promotes hepatocyte ballooning. World J Gastroenterol 2016; 22(28): 6509-6519 [PMID: 27605885 DOI: 10.3748/wjg.v22.i28.6509] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
518 Qi J, Kim JW, Zhou Z, Lim CW, Kim B. Ferroptosis Affects the Progression of Nonalcoholic Steatohepatitis via the Modulation of Lipid Peroxidation-Mediated Cell Death in Mice. Am J Pathol 2020;190:68-81. [PMID: 31610178 DOI: 10.1016/j.ajpath.2019.09.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
519 Panasevich MR, Meers GM, Linden MA, Booth FW, Perfield JW 2nd, Fritsche KL, Wankhade UD, Chintapalli SV, Shankar K, Ibdah JA, Rector RS. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. Am J Physiol Endocrinol Metab 2018;314:E78-92. [PMID: 28899857 DOI: 10.1152/ajpendo.00015.2017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
520 Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez-Arranz I, Alonso C, Ortiz Betes P, Mato JM, Cusi K. Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2018;20:1702-9. [PMID: 29527789 DOI: 10.1111/dom.13285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
521 Georgoulis M, Fragopoulou E, Kontogianni MD, Margariti A, Boulamatsi O, Detopoulou P, Tiniakos D, Zafiropoulou R, Papatheodoridis G. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. Nutr Res 2015;35:41-8. [PMID: 25530013 DOI: 10.1016/j.nutres.2014.11.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
522 Bedossa P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver Int. 2018;38 Suppl 1:64-66. [PMID: 29427497 DOI: 10.1111/liv.13653] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
523 Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus. Hepatol Res. 2019;49:531-539. [PMID: 30577089 DOI: 10.1111/hepr.13304] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
524 Sundaram SS, Halbower A, Pan Z, Robbins K, Capocelli KE, Klawitter J, Shearn CT, Sokol RJ. Nocturnal hypoxia-induced oxidative stress promotes progression of pediatric non-alcoholic fatty liver disease. J Hepatol 2016;65:560-9. [PMID: 27501738 DOI: 10.1016/j.jhep.2016.04.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
525 Ding C, Zhao Y, Shi X, Zhang N, Zu G, Li Z, Zhou J, Gao D, Lv L, Tian X, Yao J. New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci Rep 2016;6:28734. [PMID: 27345365 DOI: 10.1038/srep28734] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
526 Schumacher JD, Guo GL. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handb Exp Pharmacol 2019;256:325-57. [PMID: 31201553 DOI: 10.1007/164_2019_228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
527 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
528 Chen Y, Lu W, Jin Z, Yu J, Shi B. Carbenoxolone ameliorates hepatic lipid metabolism and inflammation in obese mice induced by high fat diet via regulating the JAK2/STAT3 signaling pathway. International Immunopharmacology 2019;74:105498. [DOI: 10.1016/j.intimp.2019.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
529 Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2013;57:81-92. [PMID: 22508243 DOI: 10.1002/hep.25789] [Cited by in Crossref: 159] [Cited by in F6Publishing: 152] [Article Influence: 17.7] [Reference Citation Analysis]
530 Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun 2018;2:48-57. [PMID: 29404512 DOI: 10.1002/hep4.1124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
531 Xiao J, Xing F, Huo J, Fung ML, Liong EC, Ching YP, Xu A, Chang RC, So KF, Tipoe GL. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep. 2014;4:5587. [PMID: 24998389 DOI: 10.1038/srep05587] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]
532 Amano Y, Shimizu F, Yasuno H, Harada A, Tsuchiya S, Isono O, Nagabukuro H, Tozawa R. Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge. Hepatol Res 2017;47:103-15. [PMID: 26992446 DOI: 10.1111/hepr.12709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
533 Seko Y, Yamaguchi K, Tochiki N, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, Umemura A, Moriguchi M, Tanaka S, Mori K, Okanoue T, Itoh Y. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1686-92. [PMID: 32342668 DOI: 10.1111/liv.14495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
534 Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011;44:652-9. [DOI: 10.1590/s0100-879x2011007500083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
535 Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol 2014; 20(16): 4702-4711 [PMID: 24782622 DOI: 10.3748/wjg.v20.i16.4702] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
536 Walcott-Sapp S, Billingsley KG. Preoperative optimization for major hepatic resection. Langenbecks Arch Surg 2018;403:23-35. [PMID: 29150719 DOI: 10.1007/s00423-017-1638-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
537 Toriguchi K, Hatano E, Sakurai T, Seo S, Taura K, Uemoto S. Laparoscopic liver resection in obese patients. World J Surg 2015;39:1210-5. [PMID: 25561194 DOI: 10.1007/s00268-014-2927-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
538 St Pierre TG, House MJ, Bangma SJ, Pang W, Bathgate A, Gan EK, Ayonrinde OT, Bhathal PS, Clouston A, Olynyk JK, Adams LA. Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. PLoS One 2016;11:e0160789. [PMID: 27501242 DOI: 10.1371/journal.pone.0160789] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
539 Aguilar-olivos NE, Carrillo-córdova D, Oria-hernández J, Sánchez-valle V, Ponciano-rodríguez G, Ramírez-jaramillo M, Chablé-montero F, Chávez-tapia NC, Uribe M, Méndez-sánchez N. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Annals of Hepatology 2015;14:487-93. [DOI: 10.1016/s1665-2681(19)31170-6] [Cited by in Crossref: 42] [Article Influence: 6.0] [Reference Citation Analysis]
540 Xin G, Qin S, Wang S, Wang X, Zhang Y, Wang J. Sex hormone affects the severity of non-alcoholic steatohepatitis through the MyD88-dependent IL-6 signaling pathway. Exp Biol Med (Maywood) 2015;240:1279-86. [PMID: 25790822 DOI: 10.1177/1535370215570189] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
541 Haczeyni F, Barn V, Mridha AR, Yeh MM, Estevez E, Febbraio MA, Nolan CJ, Bell-Anderson KS, Teoh NC, Farrell GC. Exercise improves adipose function and inflammation and ameliorates fatty liver disease in obese diabetic mice. Obesity (Silver Spring) 2015;23:1845-55. [PMID: 26250514 DOI: 10.1002/oby.21170] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
542 Carter-kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, Mccullough AJ, Feldstein AE. Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2011;52:190-7. [DOI: 10.1097/mpg.0b013e3181fb47d3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
543 Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol. 2010;53:542-550. [PMID: 20557969 DOI: 10.1016/j.jhep.2010.03.016] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 9.0] [Reference Citation Analysis]
544 Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; NASH CRN. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology 2016;151:1141-1154.e9. [PMID: 27569726 DOI: 10.1053/j.gastro.2016.08.027] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
545 Gianturco V, Troisi G, Bellomo A, Bernardini S, D'Ottavio E, Formosa V, Iacono CL, Verrusio W, Marigliano B, Marigliano V. Impact of combined therapy with alpha-lipoic and ursodeoxycolic acid on nonalcoholic fatty liver disease: double-blind, randomized clinical trial of efficacy and safety. Hepatol Int 2013;7:570-6. [PMID: 26201789 DOI: 10.1007/s12072-012-9387-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
546 Zhuang Z, Qu H, Yang W, Liu J, Wang F, Liu Y, Ding J, Shi J. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. Ann Hepatol. 2020;19:313-319. [PMID: 31870745 DOI: 10.1016/j.aohep.2019.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
547 Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol. 2012;81:e325-e331. [PMID: 22119555 DOI: 10.1016/j.ejrad.2011.10.029] [Cited by in Crossref: 129] [Cited by in F6Publishing: 117] [Article Influence: 11.7] [Reference Citation Analysis]
548 Saco A, Diaz A, Hernandez M, Martinez D, Montironi C, Castillo P, Rakislova N, del Pino M, Martinez A, Ordi J. Validation of whole-slide imaging in the primary diagnosis of liver biopsies in a University Hospital. Digestive and Liver Disease 2017;49:1240-6. [DOI: 10.1016/j.dld.2017.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
549 Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res 2013;46:270-7. [PMID: 23532271 DOI: 10.1590/1414-431x20122551] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
550 Hano H, Takasaki S, Kobayashi H, Koyama T, Lu T, Nagatsuma K. In the non-cirrhotic stage of nonalcoholic steatohepatitis, angioarchitecture of portal veins and lobular architecture are maintained. Virchows Arch 2013;462:533-40. [PMID: 23536281 DOI: 10.1007/s00428-013-1402-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
551 Odena G, Chen J, Lozano JJ, Altamirano J, Rodrigo-Torres D, Affo S, Morales-Ibanez O, Matsushita H, Zou J, Dumitru R, Caballeria J, Gines P, Arroyo V, You M, Rautou PE, Valla D, Crews F, Seki E, Sancho-Bru P, Bataller R. LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Sci Rep 2016;6:35610. [PMID: 27752144 DOI: 10.1038/srep35610] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
552 Rolle A, Paredes S, Cortínez LI, Anderson BJ, Quezada N, Solari S, Allende F, Torres J, Cabrera D, Contreras V, Carmona J, Ramírez C, Oliveros AM, Ibacache M. Dexmedetomidine metabolic clearance is not affected by fat mass in obese patients. Br J Anaesth 2018;120:969-77. [PMID: 29661414 DOI: 10.1016/j.bja.2018.01.040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
553 Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. Probiotics Antimicrob Proteins. 2017;9:123-130. [PMID: 27660157 DOI: 10.1007/s12602-016-9230-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
554 Shang Y, Nasr P, Ekstedt M, Widman L, Stål P, Hultcrantz R, Kechagias S, Hagström H. Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Rep 2021;3:100218. [PMID: 33554097 DOI: 10.1016/j.jhepr.2020.100218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
555 Fonseca TL, Fernandes GW, Bocco BMLC, Keshavarzian A, Jakate S, Donohue TM Jr, Gereben B, Bianco AC. Hepatic Inactivation of the Type 2 Deiodinase Confers Resistance to Alcoholic Liver Steatosis. Alcohol Clin Exp Res 2019;43:1376-83. [PMID: 30908637 DOI: 10.1111/acer.14027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
556 Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, Cammà C, Barcellona MR, Cabibi D, Donati B, Fracanzani A. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One. 2013;8:e74089. [PMID: 24069270 DOI: 10.1371/journal.pone.0074089] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
557 Sugimoto K, Moriyasu F, Oshiro H, Takeuchi H, Abe M, Yoshimasu Y, Kasai Y, Sakamaki K, Hara T, Itoi T. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis. Radiology 2020;296:532-40. [PMID: 32573385 DOI: 10.1148/radiol.2020192665] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
558 Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, Schattenberg JM, Barritt AS, Noureddin M, Bonacci M, Cawkwell G, Wong B, Rinella M; REGENERATE Study Investigators. Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00751-5. [PMID: 34274514 DOI: 10.1016/j.cgh.2021.07.020] [Reference Citation Analysis]
559 Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, Königsrainer A, Bischoff SC, Bergheim I. Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD). Dig Dis Sci 2012;57:1932-41. [DOI: 10.1007/s10620-012-2112-9] [Cited by in Crossref: 163] [Cited by in F6Publishing: 162] [Article Influence: 16.3] [Reference Citation Analysis]
560 Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 2012;11:2521-32. [PMID: 22364559 DOI: 10.1021/pr201223p] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 12.5] [Reference Citation Analysis]
561 Bagci R, Sahinturk V, Sahin E. Azoramide ameliorates fructose-induced nonalcoholic fatty liver disease in mice. Tissue and Cell 2019;59:62-9. [DOI: 10.1016/j.tice.2019.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
562 Igarashi H, Shigiyama F, Wakui N, Nagai H, Shibuya K, Shiraga N, Hirose T, Kumashiro N. Whole hepatic lipid volume quantification and color mapping by multi-slice and multi-point magnetic resonance imaging. Hepatol Res 2019;49:1374-85. [PMID: 31313870 DOI: 10.1111/hepr.13408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
563 Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, Hamdorf J, Adams LA. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. Am J Gastroenterol 2018;113:1484-93. [PMID: 29899440 DOI: 10.1038/s41395-018-0133-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
564 Biberci Keskin E, Coban G. Evaluation of Liver Biopsy Findings and Comparison with Noninvasive Fibrosis Scores in Patients with Non-Alcoholic Steatohepatitis. Medeni Med J 2019;34:354-9. [PMID: 32821461 DOI: 10.5222/MMJ.2019.48640] [Reference Citation Analysis]
565 Chen T, Yuan F, Wang H, Tian Y, He L, Shao Y, Li N, Liu Z. Perilla Oil Supplementation Ameliorates High-Fat/High-Cholesterol Diet Induced Nonalcoholic Fatty Liver Disease in Rats via Enhanced Fecal Cholesterol and Bile Acid Excretion. Biomed Res Int 2016;2016:2384561. [PMID: 27642591 DOI: 10.1155/2016/2384561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
566 Polyzos SA, Kountouras J, Tsatsoulis A, Zafeiriadou E, Katsiki E, Patsiaoura K, Zavos C, Anastasiadou VV, Slavakis A. Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones (Athens) 2013;12:405-16. [PMID: 24121382 DOI: 10.1007/BF03401306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
567 Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645-649. [PMID: 20400911 DOI: 10.1097/mpg.0b013e3181c7bdf1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
568 Pan X, Zhang Y, Kim HG, Liangpunsakul S, Dong XC. FOXO transcription factors protect against the diet-induced fatty liver disease. Sci Rep 2017;7:44597. [PMID: 28300161 DOI: 10.1038/srep44597] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
569 Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, Stravitz RT, Puri P, Matherly S, Sterling RK. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000-1008.e3. [PMID: 25311381 DOI: 10.1016/j.cgh.2014.10.008] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 13.0] [Reference Citation Analysis]
570 Khalil A, Cevik SE, Hung S, Kolla S, Roy MA, Suvorov A. Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Permanently Alters Blood-Liver Balance of Lipids in Male Mice. Front Endocrinol (Lausanne) 2018;9:548. [PMID: 30294300 DOI: 10.3389/fendo.2018.00548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
571 Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Journal of Hepatology 2019;71:1012-21. [DOI: 10.1016/j.jhep.2019.06.031] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 17.3] [Reference Citation Analysis]
572 Boursier J, Chaigneau J, Roullier V, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Deugnier Y, Rousselet MC, Cavaro-Ménard C, Gallois Y, Aubé C, Calès P; Study group UNAM-METABOL. Steatosis degree, measured by morphometry, is linked to other liver lesions and metabolic syndrome components in patients with NAFLD. Eur J Gastroenterol Hepatol 2011;23:974-81. [PMID: 21904208 DOI: 10.1097/MEG.0b013e32834a4d82] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
573 Yue R, Jin G, Wei S, Huang H, Su L, Zhang C, Xu Y, Yang J, Liu M, Chu Z, Yu C. Immunoregulatory Effect of Koumine on Nonalcoholic Fatty Liver Disease Rats. J Immunol Res 2019;2019:8325102. [PMID: 30915371 DOI: 10.1155/2019/8325102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
574 Ott-Fontes PR, Diedrich Neto JA, Goldoni MB. Comparison of the severity of non-alcoholic fatty liver disease in diabetic and non-diabetic obese patients. Rev Col Bras Cir 2020;47:e20202485. [PMID: 32638913 DOI: 10.1590/0100-6991e-20202485] [Reference Citation Analysis]
575 Ditzel EJ, Nguyen T, Parker P, Camenisch TD. Effects of Arsenite Exposure during Fetal Development on Energy Metabolism and Susceptibility to Diet-Induced Fatty Liver Disease in Male Mice. Environ Health Perspect 2016;124:201-9. [PMID: 26151952 DOI: 10.1289/ehp.1409501] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 7.1] [Reference Citation Analysis]
576 Klaebel JH, Skjødt M, Skat-Rørdam J, Rakipovski G, Ipsen DH, Schou-Pedersen AMV, Lykkesfeldt J, Tveden-Nyborg P. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model. Nutrients 2019;11:E2834. [PMID: 31752351 DOI: 10.3390/nu11112834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
577 Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:213-221. [PMID: 26212089 DOI: 10.1111/jgh.13058] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
578 Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Kim IH, Lee SY, Kim BH, Kim JW, Lee CH, Yeon JE, Kwon SY, Um SH, Byun KS. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00157. [PMID: 32251018 DOI: 10.14309/ctg.0000000000000157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
579 Wang X, Cao Y, Fu Y, Guo G, Zhang X. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis 2011;10:234. [PMID: 22165986 DOI: 10.1186/1476-511X-10-234] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
580 Gonzalez-Valdivieso J, Garcia-Sampedro A, Hall AR, Girotti A, Arias FJ, Pereira SP, Acedo P. Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy. ACS Appl Mater Interfaces 2021;13:55790-805. [PMID: 34788541 DOI: 10.1021/acsami.1c14592] [Reference Citation Analysis]
581 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
582 Ma Y, Tan Z, Li Q, Fan W, Chen G, Bin Y, Zhou Y, Yi J, Luo X, Tan J, Si Z, Li J. Combined Analysis of Expression Profiles in a Mouse Model and Patients Identified BHMT2 as a New Regulator of Lipid Metabolism in Metabolic-Associated Fatty Liver Disease. Front Cell Dev Biol 2021;9:741710. [PMID: 34869329 DOI: 10.3389/fcell.2021.741710] [Reference Citation Analysis]
583 Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-433; quiz e50. [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023] [Cited by in Crossref: 258] [Cited by in F6Publishing: 237] [Article Influence: 23.5] [Reference Citation Analysis]
584 Kakiuchi T, Sakata Y. Non-alcoholic steatohepatitis in a Japanese obese child. Postgrad Med J 2021:postgradmedj-2020-138951. [PMID: 34083367 DOI: 10.1136/postgradmedj-2020-138951] [Reference Citation Analysis]
585 Xanthakos SA. Nonalcoholic steatohepatitis in children with severe obesity: A global concern. Surg Obes Relat Dis 2017;13:1609-11. [PMID: 28935179 DOI: 10.1016/j.soard.2017.06.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
586 Ulitsky A, Ananthakrishnan AN, Komorowski R, Wallace J, Surapaneni SN, Franco J, Saeian K, Gawrieh S. A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. OBES SURG 2010;20:685-91. [DOI: 10.1007/s11695-010-0118-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
587 Koretz RL. JPEN Journal Club 57. The Hawthorne Effect. JPEN J Parenter Enteral Nutr 2021;45:657-9. [PMID: 32696995 DOI: 10.1002/jpen.1964] [Reference Citation Analysis]
588 Gabbi C, Bertolotti M, Anzivino C, Macchioni D, Del Puppo M, Ricchi M, Carubbi F, Tagliafico E, Romagnoli D, Odoardi MR, Loria P, Losi L, Carulli N. Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Digestive and Liver Disease 2012;44:1018-26. [DOI: 10.1016/j.dld.2012.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
589 Maurice JB, Garvey L, Tsochatzis EA, Wiltshire M, Cooke G, Guppy N, McDonald J, Marchesi J, Nelson M, Kelleher P, Goldin R, Thursz M, Lemoine M. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS 2019;33:805-14. [PMID: 30882489 DOI: 10.1097/QAD.0000000000002133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
590 Zhang Y, Li F, Jiang X, Jiang X, Wang Y, Zhang H, Zhang L, Fan S, Xin L, Yang B, Ji G, Huang C. Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice. Phytother Res 2020;34:3168-79. [PMID: 32592532 DOI: 10.1002/ptr.6747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
591 Fitzpatrick E. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proc Nutr Soc 2019;78:362-71. [DOI: 10.1017/s0029665118002914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
592 Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL, Chang CJ. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol 2013;59:1065-72. [PMID: 23792031 DOI: 10.1016/j.jhep.2013.06.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
593 Hotta K, Kitamoto T, Kitamoto A, Ogawa Y, Honda Y, Kessoku T, Yoneda M, Imajo K, Tomeno W, Saito S, Nakajima A. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. Hepatol Res 2018;48:E320-34. [PMID: 29059699 DOI: 10.1111/hepr.12992] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
594 Teufel U, Peccerella T, Engelmann G, Bruckner T, Flechtenmacher C, Millonig G, Stickel F, Hoffmann GF, Schirmacher P, Mueller S, Bartsch H, Seitz HK. Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr 2015;4:426-35. [PMID: 26734629 DOI: 10.3978/j.issn.2304-3881.2015.12.03] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
595 Torp N, Israelsen M, Nielsen MJ, Åstrand CP, Juhl P, Johansen S, Hansen CD, Madsen B, Villesen IF, Leeming DJ, Thiele M, Hansen T, Karsdal M, Krag A. Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3). Liver Int 2022;42:92-101. [PMID: 34845832 DOI: 10.1111/liv.15120] [Reference Citation Analysis]
596 Canivet CM, Bonnafous S, Rousseau D, Leclere PS, Lacas-Gervais S, Patouraux S, Sans A, Luci C, Bailly-Maitre B, Iannelli A, Tran A, Anty R, Gual P. Hepatic FNDC5 is a potential local protective factor against Non-Alcoholic Fatty Liver. Biochim Biophys Acta Mol Basis Dis 2020;1866:165705. [PMID: 32001301 DOI: 10.1016/j.bbadis.2020.165705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
597 Toda-Oti KS, Stefano JT, Cavaleiro AM, Carrilho FJ, Correa-Gianella ML, Oliveira CPMS. Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. Metab Syndr Relat Disord 2022. [PMID: 35020496 DOI: 10.1089/met.2020.0104] [Reference Citation Analysis]
598 Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi S, Mariani R, Dongiovanni P, Fracanzani AL, Fargion S. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World J Gastroenterol 2012; 18(22): 2813-2820 [PMID: 22719190 DOI: 10.3748/wjg.v18.i22.2813] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
599 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 154] [Article Influence: 55.0] [Reference Citation Analysis]
600 Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Shiratori K. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010;45:960-967. [PMID: 20376504 DOI: 10.1007/s00535-010-0237-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
601 Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P, Metrakos P. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) 2010;12:37-42. [PMID: 20495643 DOI: 10.1111/j.1477-2574.2009.00119.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
602 Valencia Deray KG, Hosek KE, Chilukuri D, Dunson JR, Spielberg DR, Swartz SJ, Spinner JA, Leung DH, Moulton EA, Munoz FM, Demmler-Harrison GJ, Bocchini CE. Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant 2021. [PMID: 34467658 DOI: 10.1111/ajt.16822] [Reference Citation Analysis]
603 Somda S, Lebrun A, Tranchart H, Lamouri K, Prevot S, Njike-Nakseu M, Gaillard M, Lainas P, Balian A, Dagher I, Perlemuter G, Naveau S, Voican CS. Adaptation of controlled attenuation parameter (CAP) measurement depth in morbidly obese patients addressed for bariatric surgery. PLoS One 2019;14:e0217093. [PMID: 31125357 DOI: 10.1371/journal.pone.0217093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
604 Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci 2016;61:1282-93. [PMID: 26856717 DOI: 10.1007/s10620-016-4054-0] [Cited by in Crossref: 251] [Cited by in F6Publishing: 229] [Article Influence: 41.8] [Reference Citation Analysis]
605 Gallego-Durán R, Ampuero J, Funuyet J, Romero-Gómez M. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?]. Gastroenterol Hepatol. 2013;36:587-596. [PMID: 24011648 DOI: 10.1016/j.gastrohep.2013.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
606 Metwally M, Bayoumi A, Khan A, Adams LA, Aller R, García-Monzón C, Arias-Loste MT, Bugianesi E, Miele L, Anna A, Latchoumanin O, Han S, Alenizi S, Sharkawy RE, Elattar A, Gallego-Durán R, Fischer J, Berg T, Liddle C, Romero-Gomez M, George J, Eslam M. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. EBioMedicine 2021;70:103521. [PMID: 34388518 DOI: 10.1016/j.ebiom.2021.103521] [Reference Citation Analysis]
607 Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond). 2011;120:239-250. [PMID: 20929443 DOI: 10.1042/cs20100387] [Cited by in Crossref: 82] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
608 Nilsson E, Matte A, Perfilyev A, de Mello VD, Käkelä P, Pihlajamäki J, Ling C. Epigenetic Alterations in Human Liver From Subjects With Type 2 Diabetes in Parallel With Reduced Folate Levels. J Clin Endocrinol Metab 2015;100:E1491-501. [PMID: 26418287 DOI: 10.1210/jc.2015-3204] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 13.0] [Reference Citation Analysis]
609 Liu J, Xiao Y, Wu X, Jiang L, Yang S, Ding Z, Fang Z, Hua H, Kirby MS, Shou J. A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genomics 2018;19:188. [PMID: 29523084 DOI: 10.1186/s12864-018-4575-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
610 Mulaikal TA, Emond JC. Physiology and Anatomy of the Liver. In: Wagener G, editor. Liver Anesthesiology and Critical Care Medicine. Cham: Springer International Publishing; 2018. pp. 3-19. [DOI: 10.1007/978-3-319-64298-7_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
611 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 17.7] [Reference Citation Analysis]
612 Gutiérrez-de-Juan V, López de Davalillo S, Fernández-Ramos D, Barbier-Torres L, Zubiete-Franco I, Fernández-Tussy P, Simon J, Lopitz-Otsoa F, de Las Heras J, Iruzubieta P, Arias-Loste MT, Villa E, Crespo J, Andrade R, Lucena MI, Varela-Rey M, Lu SC, Mato JM, Delgado TC, Martínez-Chantar ML. A morphological method for ammonia detection in liver. PLoS One 2017;12:e0173914. [PMID: 28319158 DOI: 10.1371/journal.pone.0173914] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
613 Bordoloi J, Ozah D, Bora T, Kalita J, Manna P. Gamma-glutamyl carboxylated Gas6 mediates the beneficial effect of vitamin K on lowering hyperlipidemia via regulating the AMPK/SREBP1/PPARα signaling cascade of lipid metabolism. The Journal of Nutritional Biochemistry 2019;70:174-84. [DOI: 10.1016/j.jnutbio.2019.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
614 Zhou JY, Jiang ZA, Zhao CY, Zhen Z, Wang W, Nanji AA. Long-term binge and escalating ethanol exposure causes necroinflammation and fibrosis in rat liver. Alcohol Clin Exp Res. 2013;37:213-222. [PMID: 23009062 DOI: 10.1111/j.1530-0277.2012.01936.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
615 Liu D, Wang K, Li K, Xu R, Chang X, Zhu Y, Sun P, Han X. Ets-1 deficiency alleviates nonalcoholic steatohepatitis via weakening TGF-β1 signaling-mediated hepatocyte apoptosis. Cell Death Dis 2019;10:458. [PMID: 31189885 DOI: 10.1038/s41419-019-1672-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
616 Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver Int 2017;37:1074-81. [PMID: 28097795 DOI: 10.1111/liv.13362] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
617 Machado RM, Stefano JT, Oliveira CP, Mello ES, Ferreira FD, Nunes VS, de Lima VM, Quintão EC, Catanozi S, Nakandakare ER, Lottenberg AM. Intake of trans fatty acids causes nonalcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr 2010;140:1127-32. [PMID: 20357081 DOI: 10.3945/jn.109.117937] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
618 Henegar C, Tordjman J, Achard V, Lacasa D, Cremer I, Guerre-Millo M, Poitou C, Basdevant A, Stich V, Viguerie N, Langin D, Bedossa P, Zucker JD, Clement K. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol 2008;9:R14. [PMID: 18208606 DOI: 10.1186/gb-2008-9-1-r14] [Cited by in Crossref: 281] [Cited by in F6Publishing: 251] [Article Influence: 20.1] [Reference Citation Analysis]
619 Huang JF, Yeh ML, Yu ML, Huang CF, Dai CY, Hsieh MY, Hsieh MH, Huang CI, Lin ZY, Chen SC, Hsiao PJ, Shin SJ, Chuang WL. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. PLoS One 2015;10:e0139796. [PMID: 26441244 DOI: 10.1371/journal.pone.0139796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
620 Bernsmeier C, Weisskopf DM, Pflueger MO, Mosimann J, Campana B, Terracciano L, Beglinger C, Heim MH, Cajochen C. Sleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy Controls. PLoS One. 2015;10:e0143293. [PMID: 26576055 DOI: 10.1371/journal.pone.0143293] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
621 Liu X, Guo Y, Li Z, Gong Y. The role of acylated ghrelin and unacylated ghrelin in the blood and hypothalamus and their interaction with nonalcoholic fatty liver disease. Iran J Basic Med Sci 2020;23:1191-6. [PMID: 32963741 DOI: 10.22038/ijbms.2020.45356.10555] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
622 Troelstra MA, Witjes JJ, van Dijk AM, Mak AL, Gurney-Champion O, Runge JH, Zwirs D, Stols-Gonçalves D, Zwinderman AH, Ten Wolde M, Monajemi H, Ramsoekh S, Sinkus R, van Delden OM, Beuers UH, Verheij J, Nieuwdorp M, Nederveen AJ, Holleboom AG. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort. J Magn Reson Imaging 2021. [PMID: 33991378 DOI: 10.1002/jmri.27703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
623 Rosso N, Stephenson AM, Giraudi PJ, Tiribelli C. Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. Ann Transl Med 2021;9:727. [PMID: 33987425 DOI: 10.21037/atm-20-4723] [Reference Citation Analysis]
624 Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-97. [PMID: 22183689 DOI: 10.1002/hep.25539] [Cited by in Crossref: 230] [Cited by in F6Publishing: 212] [Article Influence: 23.0] [Reference Citation Analysis]
625 Lee DH, Cho EJ, Bae JS, Lee JY, Yu SJ, Kim H, Lee KB, Han JK, Choi BI. Accuracy of Two-Dimensional Shear Wave Elastography and Attenuation Imaging for Evaluation of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021;19:797-805.e7. [PMID: 32450363 DOI: 10.1016/j.cgh.2020.05.034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
626 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
627 Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018;91:20170959. [PMID: 29722568 DOI: 10.1259/bjr.20170959] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
628 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
629 Pierce AA, Duwaerts CC, Soon RK, Siao K, Grenert JP, Fitch M, Hellerstein MK, Beysen C, Turner SM, Maher JJ. Isocaloric manipulation of macronutrients within a high-carbohydrate/moderate-fat diet induces unique effects on hepatic lipogenesis, steatosis and liver injury. J Nutr Biochem 2016;29:12-20. [PMID: 26895660 DOI: 10.1016/j.jnutbio.2015.10.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
630 Li Y, Hai J, Li L, Chen X, Peng H, Cao M, Zhang Q. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 2013;43:376-86. [DOI: 10.1007/s12020-012-9761-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
631 Sookoian S, Gianotti TF, Rosselli MS, Burgueño AL, Castaño GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 2011;218:378-85. [DOI: 10.1016/j.atherosclerosis.2011.05.014] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
632 Xie L, Yui J, Hatori A, Yamasaki T, Kumata K, Wakizaka H, Yoshida Y, Fujinaga M, Kawamura K, Zhang M. Translocator protein (18kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. Journal of Hepatology 2012;57:1076-82. [DOI: 10.1016/j.jhep.2012.07.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
633 Tordjman J, Divoux A, Prifti E, Poitou C, Pelloux V, Hugol D, Basdevant A, Bouillot JL, Chevallier JM, Bedossa P, Guerre-Millo M, Clement K. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. J Hepatol 2012;56:1152-8. [PMID: 22245892 DOI: 10.1016/j.jhep.2011.12.015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.5] [Reference Citation Analysis]
634 Hörbelt T, Knebel B, Fahlbusch P, Barbosa D, de Wiza DH, Van de Velde F, Van Nieuwenhove Y, Lapauw B, Thoresen GH, Al-hasani H, Müller-wieland D, Ouwens DM, Kotzka J. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:2671-84. [DOI: 10.1016/j.bbadis.2019.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
635 Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. Hepatol Commun 2017;1:609-22. [PMID: 29130075 DOI: 10.1002/hep4.1068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
636 Lasker S, Rahman MM, Parvez F, Zamila M, Miah P, Nahar K, Kabir F, Sharmin SB, Subhan N, Ahsan GU, Alam MA. High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation. Sci Rep 2019;9:20026. [PMID: 31882854 DOI: 10.1038/s41598-019-56538-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
637 Fernandez ML. Lifestyle Factors and Genetic Variants Associated to Health Disparities in the Hispanic Population. Nutrients 2021;13:2189. [PMID: 34202120 DOI: 10.3390/nu13072189] [Reference Citation Analysis]
638 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
639 Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-1090. [PMID: 17654743 DOI: 10.1002/hep.21763] [Cited by in Crossref: 776] [Cited by in F6Publishing: 733] [Article Influence: 51.7] [Reference Citation Analysis]
640 Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Wróblewski T, Remiszewski P, Grodzicki M, Krawczyk M. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial. Ann Surg 2017;266:738-45. [PMID: 28767558 DOI: 10.1097/SLA.0000000000002397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 8.6] [Reference Citation Analysis]
641 Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology. 2010;52:1274-1280. [PMID: 20648474 DOI: 10.1002/hep.23823] [Cited by in Crossref: 182] [Cited by in F6Publishing: 184] [Article Influence: 15.2] [Reference Citation Analysis]
642 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. [PMID: 26600078 DOI: 10.1002/hep.28356 doi: 10.1002/hep.28356] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
643 Nagappan A, Kim JH, Jung DY, Jung MH. Cryptotanshinone from the Salvia miltiorrhiza Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways. Int J Mol Sci 2019;21:E265. [PMID: 31906014 DOI: 10.3390/ijms21010265] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
644 Helal KM, Taylor JN, Cahyadi H, Okajima A, Tabata K, Itoh Y, Tanaka H, Fujita K, Harada Y, Komatsuzaki T. Raman spectroscopic histology using machine learning for nonalcoholic fatty liver disease. FEBS Lett 2019;593:2535-44. [PMID: 31254349 DOI: 10.1002/1873-3468.13520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
645 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
646 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
647 Canbay A, Gerken G, Bechmann LP. [Hepatic steatosis : Differential diagnostics and current aspects]. Internist (Berl) 2016;57:879-92. [PMID: 27510334 DOI: 10.1007/s00108-016-0112-0] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
648 Erden A, Kuru Öz D, Peker E, Kul M, Özalp Ateş FS, Erden İ, İdilman R. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction. Diagn Interv Radiol 2021;27:7-14. [PMID: 33290237 DOI: 10.5152/dir.2020.19654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
649 House MJ, Gan EK, Adams LA, Ayonrinde OT, Bangma SJ, Bhathal PS, Olynyk JK, St Pierre TG. Diagnostic performance of a rapid magnetic resonance imaging method of measuring hepatic steatosis. PLoS One 2013;8:e59287. [PMID: 23555650 DOI: 10.1371/journal.pone.0059287] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
650 Bazerbachi F, Vargas EJ, Matar R, Storm AC, Mounajjed TM, Topazian MD, Levy MJ, Chandrasekhara V, Abu Dayyeh BK. EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease. Gastrointest Endosc. 2019;90:926-932. [PMID: 31437454 DOI: 10.1016/j.gie.2019.08.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
651 Zhang W, Li C, Liu B, Wu R, Zou N, Xu Y, Yang Y, Zhang F, Zhou H, Wan K, Xiao X, Zhang X. Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis. Annals of Hepatology 2013;12:892-900. [DOI: 10.1016/s1665-2681(19)31294-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 2.6] [Reference Citation Analysis]
652 Abdelmalek MF, Charles ED, Sanyal AJ, Harrison SA, Neuschwander-Tetri BA, Goodman Z, Ehman RA, Karsdal M, Nakajima A, Du S, Tirucherai GS, Klinger GH, Mora J, Yamaguchi M, Shevell DE, Loomba R. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials 2021;104:106335. [PMID: 33657443 DOI: 10.1016/j.cct.2021.106335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
653 Del Ben M, Overi D, Polimeni L, Carpino G, Labbadia G, Baratta F, Pastori D, Noce V, Gaudio E, Angelico F, Mancone C. Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH. Int J Mol Sci 2018;19:E603. [PMID: 29463024 DOI: 10.3390/ijms19020603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
654 Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol. 2009;35:515-520. [PMID: 19200687 DOI: 10.1016/j.ejso.2008.12.013] [Cited by in Crossref: 119] [Cited by in F6Publishing: 104] [Article Influence: 9.2] [Reference Citation Analysis]
655 Reid D, Mcdonald B, Khalid T, Vo T, Schenck L, Surette M, Beck P, Reimer R, Probert C, Rioux K, Eksteen B. Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2016;1862:1337-44. [DOI: 10.1016/j.bbadis.2016.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
656 Marcolino Assis-júnior E, Melo AT, Pereira VBM, Wong DVT, Sousa NRP, Oliveira CMG, Malveira LRC, Moreira LS, Souza MHLP, Almeida PRC, Lima-júnior RCP. Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan. Toxicology and Applied Pharmacology 2017;327:71-9. [DOI: 10.1016/j.taap.2017.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
657 Zimny S, Pohl R, Rein-fischboeck L, Haberl EM, Krautbauer S, Weiss TS, Buechler C. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men. Experimental and Molecular Pathology 2017;103:1-8. [DOI: 10.1016/j.yexmp.2017.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
658 Auguet T, Berlanga A, Guiu-Jurado E, Terra X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernández M, Del Castillo D, Richart C. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed Res Int 2014;2014:502542. [PMID: 24864249 DOI: 10.1155/2014/502542] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
659 Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases: CAP measurement for liver steatosis. Hepatol Res 2013;43:1182-9. [DOI: 10.1111/hepr.12094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
660 Kolwankar D, Vuppalanchi R, Ethell B, Jones DR, Wrighton SA, Hall SD, Chalasani N. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol. 2007;5:388-393. [PMID: 17368239 DOI: 10.1016/j.cgh.2006.12.021] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
661 Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011;21:87-97. [PMID: 20680289 DOI: 10.1007/s00330-010-1905-5] [Cited by in Crossref: 285] [Cited by in F6Publishing: 263] [Article Influence: 23.8] [Reference Citation Analysis]
662 Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33. [PMID: